

Publications of Department of Medicine in 2022

A. Refereed Papers Included in Science Citation Index:

- ¹: 表此篇文章以榮總之名義發表。
- ²: 表此篇文章以榮總及陽明之名義發表。
- ³: 表此篇文章為國外進修時之著作。
- ⁴: 表此篇文章之第一作者為本部其它科之醫師。
- ⁵: 表此篇文章之第一作者為本院其它部科或他院之醫師。
- *: 為通訊作者
- #: Equal contribution

Gastroenterology

1. ^{2,5}Bai LY, Li CP, Shan YS, Chuang SC, Chen JS, Chiang NJ, Chen YY, Tsou HH, Chuang MH, Chiu CF, Liu TW, Chen LT*. A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma - The Taiwan Cooperative Oncology Group T1217 study. *Eur J Cancer* 2022;173:123-32. (IF:10.002)
2. ^{2,5}Chang SH, Lin PY, Wu TK, Hsu CS, Huang SW, Li ZY, Liu KT, Kao JK, Chen YJ, Wong TW, Wu CY*, Shieh JJ*. Imiquimod-induced ROS production causes lysosomal membrane permeabilization and activates caspase-8-mediated apoptosis in skin cancer cells. *J Dermatol Sci* 2022;107:142-50. (IF:5.408)
3. ^{2,4}Chang TE, Su CW*, Huang YS, Huang YH, Hou MC, Wu JC*. Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: A meta-analysis. *J Chin Med Assoc* 2022;85:30-41. (IF:3.396)
4. ^{2,5}Chang YS, Su CW, Chen SC, Chen YY, Liang YJ, Wu JC*. Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance. *Cells* 2022;11:634. (IF:7.666)
5. ^{2,5}Chen JY, Hsieh SM, Hwang SJ, Liu CS, Li XL*, Fournier M, Yeh TY, Yin JK, Samson SI. Immunogenicity and safety of high-dose quadrivalent influenza vaccine in older adults in Taiwan: A phase III, randomized, multi-center study. *Vaccine* 2022;40:6450-4. (IF:4.169)
6. ^{2,5}Chen SC, Huang YH, Chen MH, Hung YP, Lee RC, Shao YY, Chao Y*. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. *BMC Cancer* 2022;22:55. (IF:4.638)
7. ^{2,5}Chen YC, Chang TS, Chen CH, Cheng PN, Lo CC, Mo LR, Chen CT, Huang CF, Kuo HT, Huang YH, Tai CM, Peng CY, Bair MJ, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Huang JF, Yang CC, Hu JT, Lin CW, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Yang SS, Wu WC, Huang CS, Hsiung CK, Kao CN, Tsai PC, Liu CH, Lee MH, Dai CY, Kao JH, Chuang WL, Lin HC, Chen CY, Tseng KC*, Yu ML*. Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals. *Viruses-Basel* 2022;14:333. (IF:5.818)
8. ²Chen YJ, Su CW, Wei CY, Chau GY, Chen PH, Chao Y, Huang YH, Wu JC, Yang TC, Lee PC, Hou MC*. Comparison of prognoses between cirrhotic and noncirrhotic patients with

- hepatocellular carcinoma and esophageal varices undergoing surgical resection. *J Chin Med Assoc* 2022;85:679-86. (IF:3.396)
9. ^{2,5}Chen YY, Hsueh SW, Yang SH, Chiu SC, Chiang NJ, Chiu TJ, Li CP, Bai LY, Chiu CF, Chuang SC, Shan YS, Chan DCA, Chen LT, Yen CJ, Peng CM, Chen JS, Chou WC*. Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. *Am J Cancer Res* 2022;12:4267-78. (IF:5.942)
 10. ^{2,5}Cheng PN, Mo LR, Chen CT, Chen CY, Huang CF, Kuo HT, Lo CC, Tseng KC, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Chang T, Huang JF, Yang CC, Hu JT, Lin CW, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Yang SS, Wu WC, Huang CS, Chou KH, Kao CN, Tsai PC, Liu CH, Lee MH, Cheng CY, Tsai MC, Liu CJ, Dai CY, Lin HC*, Kao JH, Chuang WL, Yu ML*. Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. *Infect Dis Ther* 2022;11:485-500. (IF:6.119)
 11. ^{2,5}Chiang CH, Chang CC, Huang HC, Chen YJ, Tsai PH, Jeng SY, Hung SI, Hsieh JH, Huang HS, Chiou SH*, Lee FY*, Lee SD. Corrigendum to "Investigation of hepatoprotective activity of induced pluripotent stem cells in the mouse model of liver injury". (vol 2011, 219060, 2011). *Biomed Res Int* 2022;2022: 9794832. (IF:3.246)
 12. ^{2,5}Chiang DH, Chen CT, Wang TY, Yang YY*, Huang CC, Li TH, Huang SS, Kao SY, Chen CH, Hou MC, Sheu WHH. Enhancing the learning and transfer of preprocedural communication skills during clerkship using audio-visual material: a prospective case-controlled study over 2 years. *BMJ Open* 2022;12:e055953. (IF:3.006)
 13. ^{2,5}Chiang NJ, Tan KT*, Bai LY, Hsiao CF, Huang CY, Hung YP, Huang CJ, Chen SC, Shan YS, Chao Y, Huang YH, Lee IC, Lee PC, Su YY, Chen SJ, Yeh CN, Chen LT*, Chen MH*. Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study. *Clin Cancer Res* 2022;28:4248-57. (IF:13.801)
 14. ^{2,5}Chiu TJ, Yang SH, Chiu SC, Hsueh SW, Chiang NJ, Li CP, Bai LY, Cheng FM, Chuang SC, Shan YS, Chan DC, Chen LT, Yen CJ, Peng CM, Su YY, Chen YY, Chen JS, Chou WC*. Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin. *J Hepato-Biliary-Pancreat Sci* 2022;29:670-81. (IF:3.149)
 15. ^{2,5}D'Alessio A, Fulgenzi CAM, Nishida N, Schonlein M, von Felden J, Schulze K, Wege H, Gaillard VE, Saeed A, Wietharn B, Hildebrand H, Wu LD, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Personeni N, Pressiani T, Sharma R, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ*. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. *Hepatology* 2022;76:1000-12. (IF:17.298)
 16. ^{2,5}Fulgenzi CAM, Cheon J, D'Alessio A, Nishida N, Ang C, Marron TU, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang YH, Phen S, Naqash AR, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Kudo M, Rimassa L,

- Singal AG, Sharma R, Cortellini A, Gaillard VE, Chon HJ, Pinato DJ. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. *Eur J Cancer* 2022;175:204-13. (IF:10.002)
17. ²Guo JY, Chen HH, Lee WJ, Chen SC, Lee SD, Chen CY*. Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Gastric Bypass. *Nutrients* 2022;14:645. (IF:6.706)
 18. ^{2,5}Ho SY, Liu PH, Hsu CY, Huang YH, Liao JI, Su CW, Hou MC, Huo TI. Tumor burden score as a new prognostic surrogate in patients with hepatocellular carcinoma undergoing radiofrequency ablation: role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. *Expert Rev Gastroenterol Hepatol* 2022;16: 903-11. (IF:4.095)
 19. ^{2,5}Ho SY, Liu PH, Hsu CY, Huang YH, Liao JI, Su CW, Hou MC, Huo TI*. A New Tumor Burden Score and Albumin-Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma. *Cancers* 2022;14:649. (IF:6.575)
 20. ^{2,5}Ho SY, Liu PH, Hsu CY, Huang YH, Liao JI, Su CW, Hou MC, Huo TI. Radiofrequency Ablation versus Transarterial Chemoembolization for Hepatocellular Carcinoma within Milan Criteria: Prognostic Role of Tumor Burden Score. *Cancers* 2022;14:4207. (IF:6.575)
 21. ²Hsieh YC, Wu PS, Lin YT, Huang YH, Hou MC, Lee KC*, Lin HC. (Pro)renin receptor inhibition attenuated liver steatosis, inflammation, and fibrosis in mice with steatohepatitis. *Faseb J* 2022;36:e22526. (IF:5.834)
 22. ^{2,5}Hsu CH, Huang YH, Lin SM*, Hsu C*. AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review. *Liver Cancer* 2022;11:94-112. (IF:12.430)
 23. ²Hsu SJ, Huang HC, Pun CK, Chang CC*, Chuang CL, Huang YH, Hou MC, Lee FY. Sodium-Glucose Cotransporter-2 Inhibition Exacerbates Hepatic Encephalopathy in Biliary Cirrhotic Rats. *J Pharmacol Exp Ther* 2022;383:25-31. (IF:4.404)
 24. ^{2,5}Huang CF, Tseng KC, Cheng PN, Hung CH, Lo CC, Peng CY, Bair MJ, Yeh ML, Chen CH, Lee PL, Lin CY, Kuo HT, Chen CT, Yang CC, Huang JF, Tai CM, Hu JT, Lin CL, Su WW, Tsai WL, Huang YH, Cheng CY, Lin CL, Wang CC, Yang SS, Mo LR, Chen GY, Chang CC, Wang SJ, Huang CS, Hsieh TY, Lin CW, Lee TH, Chong LW, Huang CW, Chang SN, Tsai MC, Hsu SJ, Kao JH, Liu CJ, Liu CH, Lin HC, Lee MH, Tsai PC, Dai CY, Chuang WL, Chen CY*, Yu ML*. Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR). *Clin Gastroenterol Hepatol* 2022;20:1151-62. (IF:13.576)
 25. ²Huang HC, Chang CC, Pun CK, Tsai MH, Chuang CL, Hsu SJ*, Huang YH, Hou MC, Lee FY. α -Adrenergic blockade prevented environmental temperature reduction-induced transient portal pressure surge in cirrhotic and portal hypertensive rats. *Clin Sci (Lond)* 2022;136:1449-66. (IF:6.876)
 26. ²Huang HC, Hsu SJ, Chang CC*, Chuang CL, Hou MC, Lee FY. Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats. *Int J Mol Sci* 2022;23:7378. (IF:6.208)
 27. ²Huang HC, Hsu SJ, Chang CC*, Kao YC, Chuang CL, Hou MC, Lee FY. Lycopene treatment improves intrahepatic fibrosis and attenuates pathological angiogenesis in biliary cirrhotic rats. *J Chin Med Assoc* 2022;85:414-20. (IF:3.396)
 28. ²Huang HC, Sung YC, Li CP, Wan DH, Chao PH, Tseng YT, Liao BW, Cheng HT, Hsu FF,

- Huang CC, Chen YT, Liao YH, Hsieh HT, Shih YC, Liu IJ, Wu HC, Lu TT*, Wang J*, Chen YC*. Reversal of pancreatic desmoplasia by a tumour stroma-targeted nitric oxide nanogel overcomes TRAIL resistance in pancreatic tumours. *Gut* 2022;71:1843-55. (IF:31.793)
29. ^{2,5}Huang HH, Lin TL, Lee WJ, Chen SC, Lai WF, Lu CC, Lai HC*, Chen CY*. Impact of Metabolic Surgery on Gut Microbiota and Sera Metabolomic Patterns among Patients with Diabetes. *Int J Mol Sci* 2022;23:7797. (IF:6.208)
30. ²Huang KW, Lee PC, Chao Y, Su CW, Lee IC, Lan KH, Chu CJ, Hung YP, Chen SC, Hou MC, Huang YH*. Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma. *Ther Adv Med Oncol* 2022;14:17588359221099401. (IF:5.485)
31. ²Huang YS*, Tseng SY, Chen WW, Chang TT, Peng CY, Lo GH, Hsu CW, Hu CT, Huang YH. Clinical characteristics and outcomes of drug-induced liver injury in Taiwan: With emphasis on the impact of chronic hepatitis B infection. *J Chin Med Assoc* 2022;85:286-94. (IF:3.396)
32. ^{2,5}Huo TI*, Ho SY, Liao JI. Improving the accuracy of outcome prediction for hepatocellular carcinoma: Asia strategies. *Liver Int* 2022;42:714-5. (IF:8.754)
33. ^{2,5}Huo TI*, Ho SY, Liao JI. Comment on: Performance of non-invasive biomarkers compared with invasive methods for risk prediction of posthepatectomy liver failure in hepatocellular carcinoma. *Br J Surg* 2022;109:E119. (IF:11.782)
34. ^{2,5}Huo TI*, Ho SY, Liao JI. A commentary on "Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: A retrospective cohort study" (*Int J Surg* 2022;105:106843). *Int J Surg* 2022;106:106910. (IF:13.400)
35. ^{2,5}Huo TI*, Liao JI, Ho SY. Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet? *J Hepatol* 2022;76:987-8. (IF:30.083)
36. ^{2,5}Huo TL*, Liao JI, Ho SY. 3-Mercaptopyruvate sulfurtransferase in hepatocellular carcinoma: Is it an authentic clinical prognostic predictor? *Liver Int* 2022;42:1475. (IF:8.754)
37. ²Jheng YC[#], Wang YP[#], Lin HE, Sung KY, Chu YC, Wang HS, Jiang JK, Hou MC, Lee FY, Lu CL*. A novel machine learning-based algorithm to identify and classify lesions and anatomical landmarks in colonoscopy images. *Surg Endosc* 2022;36:640-50. (IF:3.453)
38. ^{2,5}Kao WY, Su CW*. Outcomes of atezolizumab and bevacizumab for hepatocellular carcinoma: Does age matter?. *Liver Int* 2022;42:2597-8. (IF:8.754)
39. ²Ko CC, Ho SY, Liu PH, Hsu CY, Hsia CY, Huang YH, Su CW, Lei HJ, Lee RC, Hou MC, Huo TI*. Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin-bilirubin grade. *Int J Clin Oncol* 2022;27:739-48. (IF:3.850)
40. ^{2,5}Kuo CW, Wu HL, Li CC, Cata JP, Liu HY, Hou MC, Cherng YG, Tai YH*. Long-term survival impact of high-grade complications after liver resection for hepatocellular carcinoma: A retrospective single-centre cohort study. *Med Lith* 2022;58:534. (IF:2.948)
41. ²Lee CY, Chau GY, Wei CY, Chao Y, Huang YH, Huo TI, Hou MC, Su YH, Wu JC, Su CW*. Surgical resection could provide better outcomes for patients with hepatocellular carcinoma and tumor rupture. *Sci Rep* 2022;12:8343. (IF:4.996)

42. ²Lee IC, Chao Y, Lee PC, Chen SC, Chi CT, Wu CJ, Wu KC, Hou MC, Huang YH*. Determinants of Survival and Post-Progression Outcomes by Sorafenib-Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma. *Cancers* 2022;14:2014. (IF:6.575)
43. ²Lee IC*, Lan KH, Su CW, Li CP, Chao Y, Lin HC, Hou MC, Huang YH*. Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy. *Int J Mol Sci* 2022;23:11335. (IF:6.208)
44. ²Lee IC*, Lee PC, Chao Y, Chi CT, Wu CJ, Hung YP, Su CW, Hou MC, Huang YH*. Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment. *Viruses-Basel* 2022;14:2355. (IF:5.818)
45. ²Lee PC, Chang TE, Wang YP, Lee KC, Lin YT, Chiou JJ, Huang CW, Yang UC, Li FY, Huang HC, Wu CY, Huang YH, Hou MC*. Alteration of gut microbial composition associated with the therapeutic efficacy of fecal microbiota transplantation in *Clostridium difficile* infection. *J Formos Med Assoc* 2022;121:1636-46. (IF:3.871)
46. ²Lee PC, Wu CJ, Hung YW, Lee CJ, Chi CT, Lee IC, Yu-Lun K, Chou SH, Luo JC, Hou MC, Huang YH*. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. *J Immunother Cancer* 2022;10:e004779. (IF:12.469)
47. ^{2,5}Lee SW, Chen LS, Yang SS, Huang YH, Lee TY*. Direct-acting antiviral therapy for hepatitis c virus in patients with BCLC stage B/C hepatocellular carcinoma. *Viruses-Basel* 2022;14:2316. (IF:5.818)
48. ²Liao CY, Lee CY, Wei CY, Chao Y, Huang YH, Hou MC, Su YH, Wu JC, Su CW*. Differential prognoses among male and female patients with hepatocellular carcinoma. *J Chin Med Assoc* 2022;85:554-65. (IF:3.396)
49. ^{2,5}Lin SH, Lin CY, Hsu NT, Yen YH, Kee KM, Wang JH, Hu TH, Chen CH, Hung CH, Chen CH, Hu JT, Huang YH, Wang TE, Lu SN*. Reappraisal of the roles of alpha-fetoprotein in hepatocellular carcinoma surveillance using large-scale nationwide database and hospital-based information. *J Formos Med Assoc* 2022;121:2085-92. (IF:3.871)
50. ^{2,5}Liu CJ*, Sheen IS, Chen CY, Chuang WL, Wang HY, Tseng KC, Chang TT, Yang J, Masetto B, Suri V, Camus G, Jiang DY, Zhang FQ, Gaggari A, Hu TH, Hsu YC, Lo GH, Chu CJ, Chen JJ, Peng CY, Chien RN, Chen PJ. Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment. *Clin Infect Dis* 2022;75:453-9. (IF:20.999)
51. ^{2,4}Liu YC, Su CW, Ko PS, Lee RC, Liu CJ, Huang YH, Gau JP, Liu JH*. A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma. *Asia-Pac J Clin Oncol* 2022;18:19-27. (IF:1.926)
52. ²Lo CC, Huang CF, Cheng PN, Tseng KC, Chen CY, Kuo HT, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Chang TS, Huang JF, Yang CC, Hu JT, Lin CW, Chen CT, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Mo LR, Yang SS, Wu WC, Huang CS, Hsiung CK, Kao CN, Tsai PC, Liu CH, Lee MH, Liu CJ, Dai CY, Chuang WL, Lin HC, Kao JH*, Yu ML*, Investigators. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan. *J Formos Med Assoc* 2022;121:1567-

78. (IF:3.871)

53. ²Lu HS, Yang TC, Chang CY, Huang YH, Hou MC*. The risk of variceal bleeding during endoscopic retrograde cholangiopancreatography. *J Chin Med Assoc* 2022;85:896-900. (IF:3.396)
54. ^{2,5}Marinelli B, Kim E, D'Alessio A, Cedillo M, Sinha I, Debnath N, Kudo M, Nishida N, Saeed A, Hildebrand H, Kaseb AO, Abugabal YI, Pillai A, Huang YH, Khan U, Muzaffar M, Naqash AR, Patel R, Fischman A, Bishay V, Bettinger D, Sung M, Ang C, Schwartz M, Pinato DJ, Marron T*. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. *J Immunother Cancer* 2022;10:e004205. (IF:12.469)
55. ^{2,5}Muhammed A, Fulgenzi CAM, Dharmapuri S, Pinter M, Balcar L, Scheiner B, Marron TU, Jun TM, Saeed A, Hildebrand H, Muzaffar M, Navaid M, Naqash AR, Gampa A, Ozbek U, Lin JY, Perone Y, Vincenzi B, Silletta M, Pillai A, Wang YH, Khan U, Huang YH, Bettinger D, Abugabal YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Di Tommaso L, Kudo M, Vogel A, Mauri FA, Cortellini A, Sharma R, D'Alessio A, Ang C, Pinato DJ*. The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma. *Cancers* 2022;14:186. (IF:6.575)
56. ²Pan YL, Wu PS*, Ye BW, Li CP, Lee IC, Lee KC*, Huang YH, Hou MC. Outcomes of patients with malignant esophagogastric junction obstruction receiving metallic stents: A single-center experience. *J Chin Med Assoc* 2022;85:160-6. (IF:3.396)
57. ^{1,5}Rajappa S, Rau KM, Dattatreya PS, Ramaswamy A, Fernandes P, Pruthi A, Cheng R, Lukanowski M, Huang YH*.. Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options? *World J Hepatol.* 2022;14:1074-86. (IF:3.173)
58. ^{2,5}Sarin SK*, Eslam M, Fan JG, Lin HC*, George J, Omata M. MAFLD, patient-centred care, and APASL. *Hepatol Int* 2022;16:1032-4. (IF:9.046)
59. ^{2,5}Sharma R*, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, Dharmapuri S, Szafron D, Naqash AR, Gampa A, Wang YH, Khan U, Muzaffar M, Lee CJ, Lee PC, Bulumulle A, Paul S, Bettinger D, Hildebrand H, Yehia M, Pressiani T, Kaseb A, Huang YH*, Ang C, Kudo M, Nishida N, Personeni N, Rimassa L, Pinato DJ. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. *Hepatol Commun* 2022;6:1776-85. (IF:5.701)
60. ²Su PS, Wu SH, Chu CJ*, Su CW, Lin CC, Lee SD, Wang YJ, Lee FY, Huang YH, Hou MC. Sofosbuvir-based antiviral therapy provided highly treatment efficacy, safety, and good tolerability for Taiwanese chronic hepatitis C patients with decompensated cirrhosis. *J Chin Med Assoc* 2022;85:152-9. (IF:3.396)
61. ^{2,5}Su YY, Chiang NJ, Li CP, Yen CJ, Yang SH, Chou WC, Chen JS, Chiu TJ, Chen YY, Chuang SC, Bai LY, Chiu CF, Peng CM, Chan DC, Chiu SC, Yang YH, Shan YS*, Chen LT*. Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. *Front Oncol* 2022;12:800842. (IF:5.738)
62. ^{2,5}Su YY, Chiu YF, Li CP, Yang SH, Lin OO, Lin E, Chang PY, Chiang NJ, Shan YS*, Ch'ang HJ*, Chen LZ*. A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study. *Br J Cancer* 2022;126:1018-26. (IF:9.075)

63. ²Sung KI, Wang YP*, Chang TE, Wang HS, Jiang JK, Luo JC, Lee FY, Hou MC, Lu CL. Safety and importance of colonoscopy in nonagenarians. *J Chin Med Assoc* 2022;85:304-10. (IF:3.396)
64. ²Sung KY, Chang TE, Wang YP*, Lin CC, Chang CY, Hou MC, Lu CL. SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis. *J Chin Med Assoc* 2022;85:421-30. (IF:3.396)
65. ²Sung KY, Zhang B, Wang HHE, Bai YM, Tsai SJ, Su TP, Chen TJ, Hou MC, Lu CL, Wang YP*, Chen MH*. Schizophrenia and risk of new-onset inflammatory bowel disease: a nationwide longitudinal study. *Aliment Pharmacol Ther* 2022;55:1192-201. (IF:9.524)
66. ^{2,5}Tsai CF, Chuang CH, Wang YP, Lin YB, Tu PC, Liu PY, Wu PS, Lin CY, Lu CL*. Differences in gut microbiota correlate with symptoms and regional brain volumes in patients with late-life depression. *Front Aging Neurosci* 2022;14:885393. (IF:5.702)
67. ^{2,4}Tsai HC, Tung HY, Liu CW, Su CF, Sun YS, Chen WS, Chen MH, Lai CC, Liao HT*, Yang YY, Huang YH, Tsai CY*. Significance of high serum IgG4 in complete or non-full-fledged IgG4-related disease-a retrospective investigation of 845 patients and its clinical relevance. *Clin Rheumatol* 2022;41:115-22. (IF:3.650)
68. ^{2,5}Vithayathil M, D'Alessio A, Fulgenzi CAM, Nishida N, Schonlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu LD, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Personeni N, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ, Sharma R*. Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma. *Liver Int* 2022;42:2538-47. (IF:8.754)
69. ^{2,5}Wang HW, Tsai PC, Chen CY, Tseng KC, Lai HC, Kuo HT, Hung CH, Tung SY, Wang JH, Chen JJ, Lee PL, Chien RN, Lin CY, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Su WW, Chu CH, Chen CJ, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Huang JF, Dai CY, Chuang WL, Yu ML*, Peng CY*. Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort study. *Am J Cancer Res* 2022;12:3164-74. (IF:5.942)
70. ^{2,5}Wang YK, Wang YW, Lu CL, Huang YH, Hou MC, Chang YL, Lee WP*, Lan KH*. Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol. *Sci Rep* 2022;12:9942. (IF:4.997)
71. ^{2,4}Wang YP, Jheng YC, Sung KY, Lin HE, Hsin IF, Chen PH, Chu YC, Lu D, Wang YJ, Hou MC, Lee FY, Lu CL*. Use of U-Net Convolutional Neural Networks for Automated Segmentation of Fecal Material for Objective Evaluation of Bowel Preparation Quality in Colonoscopy. *Diagnostics* 2022;12:613. (IF:3.992)
72. ²Wei TH, Ye BW, Wu PS*, Li CP, Chao Y, Lee PC, Huang YH, Lee KC*, Hou MC. Outcomes of patients with malignant duodenal obstruction after receiving self-expandable metallic stents: A single center experience. *PLoS One* 2022;17:e0268920. (IF:3.752)
73. ^{2,5}Wen MH, Bai D, Lin S, Chu CJ, Hsu YL. Implementation and experience of an innovative smart patient care system: a cross-sectional study. *BMC Health Serv Res* 2022;22:126. (IF:2.908)

74. ²Wu CJ, Lee PC, Hung YW, Lee CJ, Chi CT, Lee IC, Hou MC, Huang YH*. Lenvatinib plus pembrolizumab for systemic therapy-naive and -experienced unresectable hepatocellular carcinoma. *Cancer Immunol Immunother* 2022;71:2631-43. (IF:6.630)
75. ^{2,5}Wu CY*, Wu CY*, Li CP, Lin YH, Chang YT. Association of Immunosuppressants with Mortality of Patients with Bullous Pemphigoid: A Nationwide Population-Based Cohort Study. *Dermatology* 2022;238:378-85. (IF:5.197)
76. ^{2,5}Wu HL, Liu HY, Liu WC, Hou MC, Tai YH*. A predictive model incorporating inflammation markers for high-grade surgical complications following liver resection for hepatocellular carcinoma. *J Chin Med Assoc* 2022;85:845-52. (IF:3.396)
77. ^{2,5}Wu JW, Cheng HM, Huang SS, Liang JF, Huang CC, Shulruf B, Yang YY*, Chen CH*, Hou MC, Sheu WHH. Medical school grades may predict future clinical competence. *J Chin Med Assoc* 2022;85:909-14. (IF:3.396)
78. ^{2,5}Wu JW, Cheng HM, Huang SS, Liang JF, Huang CC, Yang LY, Shulruf B, Yang YY*, Chen CH, Hou MC, Sheu WHH. Comparison of OSCE performance between 6-and 7-year medical school curricula in Taiwan. *BMC Med Educ* 2022;22:15. (IF:3.263)
79. ^{2,5}Wu WC, Lin TY, Chen MH, Hung YP, Liu CA, Lee RC, Huang YH, Chao Y, Chen SC*. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. *Invest New Drugs* 2022;40:789-97. (IF:3.651)
80. ^{2,5}Wu YH, Hung YP, Chiu NC, Lee RC, Li CP, Chao Y, Shyr YM, Wang SE, Chen SC, Lin SH, Chen YH, Kang YM, Hsu SM, Yen SH, Wu JY, Lee KD, Tseng HE, Tsai JR, Tang JH, Chiou JF, Burnouf T, Chen YJ, Wang PY, Lu LS*. Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma. *Eur J Cancer* 2022;166:208-18. (IF:10.002)
81. ^{1,5}Yang AM*, Lin CY, Liu SH, Syu GD, Sun HJ, Lee KC*, Lin HC, Hou MC. Saccharomyces Boulardii Ameliorates Non-alcoholic Steatohepatitis in Mice Induced by a Methionine-Choline-Deficient Diet Through Gut-Liver Axis. *Front Microbiol* 2022;13:887728. (IF:6.064)
82. ^{2,5}Yang SH, Chiang NJ, Chiu SC, Chou WC, Bai LY, Li CP, Su YY, Chiu TJ, Chuang SC, Peng CM, Chan DC, Chen JS, Yen CJ, Chen YY, Chiu CF, Chen LT, Shan YS*. Original Article The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan. *Am J Cancer Res* 2022;12:1884-98. (IF:5.942)
83. ²Yang TC, Chen PH, Hou MC*, Peng LN, Lin MH, Chen LK, Huang YH. Antiperistaltic effect and safety of l-menthol for esophagogastroduodenoscopy in the elderly with contraindication to hyoscine-N-butylbromide. *Sci Rep* 2022;12:10418. (IF:4.996)
84. ^{2,5}Yang YP, Lee ACL, Lin LT, Chen YW, Huang PI, Ma HI, Chen YC, Lo WL, Lan YT, Fang WL, Wang CY, Liu YY, Hsu PK, Lin WC, Li CP, Chen MT, Chien CS*, Wang ML*. Strategic Decoy Peptides Interfere with MSI1/AGO2 Interaction to Elicit Tumor Suppression Effects. *Cancers* 2022;14:505. (IF:6.575)
85. ²Yau T*, Tai DV, Chan SL, Huang YH*, Choo SP, Hsu C, Cheung TT, Lin SM, Yong WP, Lee JYY, Leung T, Shum T, Yeung CSY, Tai AYP, Law ALY, Cheng AL, Chen LT. Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan. *Liver Cancer* 2022;11:426-39. (IF:12.430)
86. ²Ye YC, Wang SE, Wang YP*. Ileoileal Intussusception Caused by Ileal Neuroendocrine

- Carcinoma. *Clin Gastroenterol Hepatol* 2022;20:A29-30. (IF:13.576)
87. ^{2,5}Yen FS, Hsu CC, Wei JCC, Hou MC*, Hwu CM*. Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease. *Front Med* 2022;9:839456. (IF:5.058)
 88. ^{2,5}Yen FS, Huang YH, Hou MC, Hwu CM, Lo YR, Shin SJ, Hsu CC*. Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis. *Br J Clin Pharmacol* 2022;88:311-22. (IF:3.716)
 89. ^{1,5}You H, Ma X, Efe C, Wang GQ, Jeong SH, Abe K, Duan WJ, Chen S, Kong YY, Zhang D, Wei L, Wang FS, Lin HC, Yang JM, Tanwandee T, Gani RA, Payawal DA, Sharma BC, Hou JL, Yokosuka O, Dokmeci AK, Crawford D, Kao JH, Piratvisuth T, Suh DJ, Lesmana LA, Sollano J, Lau G, Sarin SK, Omata M, Tanaka A, Jia JD. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. *Hepatol Int* 2022;16:1-23. (IF:9.029)
 90. ²Yu HY, Lee CY, Lin LG, Chao Y, Li CP*. Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience. *J Chin Med Assoc* 2022;85:42-50. (IF:3.396)
 91. ²Yu HY, Li CP, Huang YH, Hsu SJ, Wang YP, Hsieh YC, Fang WL, Huang KH, Li AFY, Lee RC, Lee KL, Wu YH, Lai IC, Yang WC, Hung YP, Wang YC, Chen SH, Chen MH*, Chao Y*. Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer. *Cancers* 2022;14:218. (IF:6.575)
 92. ²Zhang B*, Wang HHE, Bai YM, Tsai SJ, Su TP, Chen TJ, Wang YP*, Chen MH*. Bidirectional association between inflammatory bowel disease and depression among patients and their unaffected siblings. *J Gastroenterol Hepatol* 2022;37:1307-15. (IF:4.369)

Cardiology

1. ¹Bruckert E*, Caprio S, Wiegman A, Charng MJ, Zarate-Morales CA, Baccara-Dinet MT, Manvelian G, Ourliac A, Scemama M, Daniels SR. Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study. *Arterioscler Thromb Vasc Biol* 2022;42:1447-57. (IF:10.514)
2. ^{2,5}Butt JH, Dewan P, Merkely B, Belohlavek J, Drozd J, Kitakaze M, Inzucchi SE, Kosiborod MN, Martinez FA, Tereshchenko S, Ponikowski P, Bengtsson O, Lindholm D, Langkilde AM, Schou M, Sjostrand M, Solomon SD, Sabatine MS, Chiang CE, Docherty KF, Jhund PS, Kober L, McMurray JJV*. Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction A Post Hoc Analysis of the DAPA-HF Trial. *Ann Intern Med* 2022;175:820-30. (IF: 51.598)
3. ^{1,5}Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, Patel MR, Wallentin L, Alexander JH, Bahit MC, Benz AP, Bohula EA, Chao TF, Dyal L, Ezekowitz M, Fox KAA, Gencer B, Halperin JL, Hijazi Z, Hohnloser SH, Hua KY, Hylek E, Kato ET, Kuder J, Lopes RD, Mahaffey KW, Oldgren J, Piccini JP, Ruff CT, Steffel J, Wojdyla D, Granger CB*. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age

- and Sex. *Circulation* 2022;145:242-55. (IF: 39.922)
4. ^{2,4}Chan CH, Hu YF*, Chen PF, Wu IC, Chen SA. Exercise Test for Patients with Long QT Syndrome. *Acta Cardiol Sin* 2022;38:124-33. (IF: 1.800)
 5. ^{2,5}Chan CS, Lin FJ, Liu CM, Lin YK, Chen YC, Hsu CC*, Higa S, Chen SA, Chen YJ*. Mirabegron, a beta 3-adrenoreceptor agonist, regulates right and left atrial arrhythmogenesis differently. *Exp Ther Med* 2022; 24:720. (IF: 2.751)
 6. ^{2,5}Chan YH*, Chao TF, Chen SW, Kao YW, Huang CY, Chu PH*. Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor. *Eur Heart J-Qual Care Clin Outcomes* 2022; qcac040. (IF: 7.064)
 7. ^{2,5}Chan YH, Chao TF, Chen SW, Lee HF, Li PR, Chen WM, Yeh YH, Kuo CT, See LC*, Lip GYH*. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. *Cardiovasc Diabetol* 2022;21:118. (IF: 8.949)
 8. ^{2,5}Chang CY, Gau ML, Huang CJ, Cheng HM*. Effects of non-pharmacological coping strategies for reducing labor pain: A systematic review and network meta-analysis. *PLoS One* 2022;17:e0261493. (IF:3.752)
 9. ^{2,5}Chang HC, Huang WM, Yu WC, Cheng HM, Guo CY, Chiang CE, Chen CH, Sung SH. Prognostic Role of Pulmonary Function in Patients With Heart Failure With Reduced Ejection Fraction. *J Am Heart Assoc* 2022;11:e023422. (IF: 6.107)
 10. ^{2,5}Chang HC, Kuo TT, Chen YY, Lin YJ, Chang HY, Hung CL*, Chung FP*. Sodium-Glucose Cotransporter 2 Inhibitors in Cardiovascular and Renal Outcomes in Patients With Diabetes but Without Established Cardiovascular Disease: A Nationwide Population-Based Cohort Study. *Diabetes Care* 2022; 45: E129-30. (IF: 17.155)
 11. ^{2,5}Chang HY*, Fang HL, Huang CY, Chiang CY, Chuang SY, Hsu CC, Cheng HM, Chen TW, Yao WC, Pan WH. Developing and Validating Risk Scores for Predicting Major Cardiovascular Events Using Population Surveys Linked with Electronic Health Insurance Records. *Int J Environ Res Public Health* 2022; 19:1319. (IF:4.614)
 12. ^{2,5}Chang LH, Chu CH, Huang CC, Lin LY*. Fibroblast Growth Factor 21 Levels Exhibit the Association With Renal Outcomes in Subjects With Type 2 Diabetes Mellitus. *Front Endocrinol* 2022;13:846018. (IF: 6.055)
 13. ^{2,5}Chang PY, Wang WT, Wu WL, Chang HC, Chen CH, Tsai YW*, Chiou SH, Lip GYH, Cheng HM*, Chiang CE. Oral Anticoagulation Timing in Patients with Acute Ischemic Stroke and Atrial Fibrillation. *Thromb Haemost* 2022;122:939-50. (IF: 6.830)
 14. ^{2,5}Chang TT*, Chen C, Chen JW. CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease. *Cardiovasc Diabetol* 2022;21:185. (IF:8.949)
 15. ^{2,5}Chang TT*, Chen C, Lin LY, Chen JW*. CCL4 Deletion Accelerates Wound Healing by Improving Endothelial Cell Functions in Diabetes Mellitus. *Biomedicines* 2022;10:1963. (IF: 4.757)
 16. ^{2,5}Chang TT*, Chen JW. Potential Impacts of Hydralazine as a Novel Antioxidant on Cardiovascular and Renal Disease-Beyond Vasodilation and Blood Pressure Lowering. *Antioxidants* 2022;11:2224. (IF: 7.675)

17. ^{2,5}Chang TT*, Chiang CH, Chen C, Lin SC, Lee HJ, Chen JW*. Antioxidation and Nrf2-mediated heme oxygenase-1 activation contribute to renal protective effects of hydralazine in diabetic nephropathy. *Biomed Pharmacother* 2022;151:113139. (IF: 7.419)
18. ²Chang TY, Chen KW, Liu CM, Chang SL*, Lin YJ, Lo LW, Hu YF, Chung FP, Lin CY, Kuo L, Chen SA. A High-Precision Deep Learning Algorithm to Localize Idiopathic Ventricular Arrhythmias. *J Pers Med* 2022;12:764. (IF: 3.508)
19. ²Chang TY, Lu CT, Huang HL, Chou RH, Chang CC, Liu CT, Huang PH*, Lin SJ. Association of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Use With Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients With Stabilized Acute Myocardial Infarction: A Propensity Score Matching Study. *Front Cardiovasc Med* 2022;9:882181. (IF: 5.848)
20. ²Chao TF*, Chan YH, Chiang CE, Tuan TC, Liao JN, Chen TJ, Lip GYH*, Chen SA. Stroke prevention with direct oral anticoagulants in high-risk elderly atrial fibrillation patients at increased bleeding risk. *Eur Heart J-Qual Care Clin Outcomes* 2022;8:730-8. (IF: 7.064)
21. ²Chao TF*, Chan YH, Chiang CE, Tuan TC, Liao JN, Chen TJ, Lip GYH, Chen SA. Early Rhythm Control and the Risks of Ischemic Stroke, Heart Failure, Mortality, and Adverse Events When Performed Early (<3 Months): A Nationwide Cohort Study of Newly Diagnosed Patients with Atrial Fibrillation. *Thromb Haemost* 2022;122:1899-910. (IF:6.830)
22. ²Chao TF*, Chan YH, Chiang CE, Tuan TCA, Liao JN, Chen TJ, Lip GYH, Chen SA. Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation. *Clin Res Cardiol* 2022;111:23-33. (IF: 6.138)
23. ²Chao TF*, Chan YH, Tuan TC, Liao JN, Chen TJ, Lip GYH, Chen SA. Should oral anticoagulants still be prescribed to patients with atrial fibrillation with a single stroke risk factor but at high bleeding risk? A nationwide cohort study. *Eur Heart J-Qual Care Clin Outcomes* 2022;8:588-95. (IF: 7.064)
24. ²Chao TF*, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, Guo YT, Sriratanasathavorn C, Oh S, Okumura K, Lip GYH. 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. *Thromb Haemost* 2022;122:20-47. (IF:6.830)
25. ²Chao TF*, Tse HF, Teo WS, Park HW, Shimizu W, Chen SA, Lip GYH. Clinical utility and prognostic implications of the 4S-AF scheme: Report from Asia Pacific Heart Rhythm Society Atrial Fibrillation Registry. *Eur J Clin Invest* 2022;52:e13825. (IF:5.722)
26. ^{2,5}Chen CT, Lin JW, Wu CH, Kuo RNC, Shih CH, Hou PC*, Yen DHT, How CK. A Simple Risk Score for Predicting Neurologic Outcome in Out-of-Hospital Cardiac Arrest Patients After Targeted Temperature Management. *Crit Care Med* 2022;50:428-39. (IF: 9.296)
27. ^{2,5}Chen HY, Huang WC, Teng HI, Tsai CT, Tsai YL, Chuang MJ, Chen YY, Lu TM*. Effects of aggressive predilatation, sizing, and postdilatation strategy for coronary bioresorbable vascular scaffolds implantation. *J Chin Med Assoc* 2022;85:543-8. (IF: 3.396)
28. ^{2,5}Chen PS, Lee M, Tang SC, Huang PH, Yeh H, Hou CJY, Hsieh C, Lee JT, Jeng JS*, Li YH* 2022 focused update of the 2017 Taiwan lipid guidelines for high risk patients: Coronary artery disease, peripheral artery disease and ischemic stroke. *J Formos Med Assoc* 2022;121:1363-70. (IF: 3.871)
29. ²Chen WT, Ahliah I, Chung FP*. Pseudo-Conduction in the Mitral Isthmus After Ablation. *Heart Lung Circ* 2022;31: E126-8. (IF: 2.838)

30. ^{2,5}Chen WT, Chi NF, Cheng HM, Ko YT, Chuang SY, Pan WH, Chen CH, Chung CP, Wang PN*. Associations Between Cerebral Vasoreactivity and Cognitive Function in the Middle-Aged Non-Demented Population. *J Alzheimers Dis* 2022;86:679-90. (IF: 4.160)
31. ^{2,5}Chen WT, Lo LW*, Tsai WC, Lin YJ, Chang SL, Hu YF, Chung FP, Liao JN, Tuan TC, Chao TF, Lin CY, Chang TY, Kuo L, Liu CM, Liu SH, Cheng WH, Lin LD, Ton ANK, Hsu CY, Chheng C, Elimam A, Wang HS, Kuo MR, Kao PH, Chen SA. Application of dynamic display technology to identify gaps after pulmonary vein isolation in catheter ablation of atrial fibrillation. *J Cardiol* 2022;80: 34-40. (IF: 3.115)
32. ²Chen YH*, Chang HH, Liao TW, Leu HB, Chen IM, Chen PL, Lin SM. Membranous septum length predicts conduction disturbances following transcatheter aortic valve replacement. *J Thorac Cardiovasc Surg* 2022;164:42-51. (IF: 6.439)
33. ^{2,5}Chen YY, Kuo MJ, Chung FP, Lin YJ*, Chien KL, Hsieh YC, Chang SL, Lo LW, Hu YF, Chao TF, Liao JN, Chang TY, Lin CY, Kuo L, Tuan TC, Wu CI, Liu CM, Liu SH, Li CH, Chen SA. Risks of Ventricular Tachyarrhythmia and Mortality in Patients with Amyloidosis - A Long-Term Cohort Study. *Acta Cardiol Sin* 2022;38: 464-74. (IF: 1.800)
34. ²Cheng WH, Chung FP*, Lin YJ, Lo LW, Chang SL, Hu YF, Tuan TC, Chao TF, Liao JN, Lin CY, Chang TY, Kuo L, Wu CI, Liu CM, Liu SH, Chen SA*. Catheter Ablation in Arrhythmic Cardiac Diseases: Endocardial and Epicardial Ablation. *Rev Cardiovasc Med* 2022;23:324. (IF:4.430)
35. ²Cheng WH, Lo LW*, Lin YJ, Chang SL, Hu YF, Chung FP, Tuan TC, Chao TF, Liao JN, Chang TY, Lin CY, Kuo L, Liu SH, Vicera JJ, Lugtu IC, Kim S, Chen SA. Identification of Circumferential Pulmonary Vein Isolation Gaps and Critical Atrial Substrate From HD Grid Maps in Atrial Fibrillation Patients: Insights From Omnipolar Technology. *Circ-Arrhythmia Electrophysiol* 2022;15:63-5. (IF:7.718)
36. ¹Cheng WL, Chen YC, Li SJ, Lee TI, Lee TW, Higa S, Chung CC, Kao YH*, Chen SA, Chen YJ*. Galectin-3 enhances atrial remodelling and arrhythmogenesis through CD98 signalling. *Acta Physiol* 2022;234: e13784. (IF:7.523)
37. ^{2,5}Chhay C, Hsu CY, Chang SL*, Lin YJ, Lo LW, Hu YF, Chung FP, Chang TY, Lin CY, Hung Y, Liu CM, Kuo L, Liu SH, Ahli L, Kuo MJ, Cheng WH, Kao PH, Chen WT, Khac TCN, Lin WS, Chen SA. Electrophysiological characteristics of epicardial breakthrough during catheter ablation of perimitral atrial flutter. *Front Cardiovasc Med* 2022;9:1030916. (IF:5.848)
38. ^{2,5}Chi NF, Chung CP*, Cheng HM, Liu CH, Lin CJ, Hsu LC, Tang SC, Lee JT, Po HL, Jeng JS, Wang TD, Lee IH. 2021 Taiwan Stroke Society Guidelines of blood pressure control for ischemic stroke prevention. *J Chin Med Assoc* 2022;85:651-64. (IF: 3.396)
39. ^{2,5}Chou PC, Liu CM, Weng CH, Yang KC, Cheng ML, Lin YC, Yang RB, Shyu BC, Shyue SK, Liu JD, Chen SP, Hsiao M, Hu YF*. Fibroblasts Drive Metabolic Reprogramming in Pacemaker Cardiomyocytes. *Circ Res* 2022;131:6-20. (IF: 23.218)
40. ²Chuang MJ, Chang CC*, Lee YH, Lu YW, Tsai YL, Chou RH, Wu CH, Lu TM, Huang PH. Clinical assessment of resting full-cycle ratio and fractional flow reserve for coronary artery disease in a real-world cohort. *Front Cardiovasc Med* 2022;9:988820. (IF:5.848)
41. ^{2,5}Chuang MM, Wu SH*, Charng MJ, Wu YJ. A Novel BMPR2 Variant Gene in Relation with Hereditary Pulmonary Arterial Hypertension Combined with Pulmonary Arteriovenous Malformations. *Acta Cardiol Sin* 2022;38:542-5. (IF: 1.800)

42. ^{2,5}Demarchi A, Conte G, Chen SA, Lo LW, Chen WT, De Potter T, Geelen P, Sarkozy A, Spera FR, Reichlin T, Roten L, Defaye P, Carabelli A, Boveda S, Bourenane H, Riesinger L, Kochhauser S, Caixal G, Mont L, Scherr D, Manninger M, Pentimalli F, Cornara S, Klersy C, Auricchio A*. Catheter Ablation of Atrial Fibrillation in Patients with Previous Lobectomy or Partial Lung Resection: Long-Term Results of an International Multicenter Study. *J Clin Med* 2022;11:1481. (IF:4.964)
43. ^{2,5}Gorog DA*, Gue YX, Chao TF, Fauchier L, Ferreiro JL, Huber K, Konstantinidis SV, Lane DA, Marin F, Oldgren J, Potpara T, Roldan V, Rubboli A, Sibbing D, Tse HF, Vilahur G, Lip GYH*. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. *Europace* 2022; 24:1844-71. (IF: 5.486)
44. ^{2,5}Gorog DA*, Gue YX, Chao TF, Fauchier L, Ferreiro JL, Huber K, Konstantinidis SV, Lane DA, Marin F, Oldgren J, Potpara T, Roldan V, Rubboli A, Sibbing D, Tse HF, Vilahur G, Lip GYH*. Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper. *Thromb Haemost* 2022;122:1625-52. (IF: 6.830)
45. ²Guo JY, Chen HH, Lee WJ, Chen SC, Lee SD, Chen CY*. Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Gastric Bypass. *Nutrients* 2022;14:645. (IF:6.706)
46. ^{2,5}Hoo CE, Kuo CS, Huang CY, Huang PH, Yang AH, Hsu CP*. Cardiac Dopamine-Secreting Paraganglioma with Involved Skull Base and Retroperitoneum After a History of Pheochromocytoma Post Adrenalectomy. *Int Heart J* 2022;63:786-92. (IF: 1.823)
47. ^{2,5}Hsiao CW, Yen TH, Wu YC, Chen JP, Chen YY, Huang WN, Chen YH, Chen YM*. Comparison of Aspergillus-specific antibody cut-offs for the diagnosis of aspergillosis. *Front Microbiol* 2022;13:1060727. (IF: 6.064)
48. ^{2,5}Hsiao FC, Yen KC, Chao TF, Chen SW, Chan YH*, Chu PH*. New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies. *J Clin Endocrinol Metab* 2022; 107: 2493-9. (IF: 6.134)
49. ^{2,5}Hsu CY, Chang HY, Chao CJ, Chiou WR, Lin PL, Chung FP, Lin WY, Huang JL, Liang HW, Liao CT, Lee YH*. Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan. *Front Cardiovasc Med* 2022;9:950389. (IF: 5.848)
50. ²Hu YF*, Lee AS, Chang SL, Lin SF, Weng CH, Lo HY, Chou PC, Tsai YN, Sung YL, Chen CC, Yang RB, Lin YC, Kuo TBJ, Wu CH, Liu JD, Chung TW, Chen SA. Biomaterial-induced conversion of quiescent cardiomyocytes into pacemaker cells in rats. *Nat Biomed Eng* 2022;6:421-34. (IF: 29.234)
51. ²Huang CC*, Chung CM, Yang CY, Leu HB, Huang PH, Lin LY, Wu TC, Lin SJ, Pan WH, Chen JW. SLC12A3 Variation and Renal Function in Chinese Patients With Hypertension. *Front Med* 2022;9:863275. (IF: 5.058)
52. ²Huang CC*, Huang YL, Lin CH*, Chen JW. Plasma metabolomic profiles associated with hypertension and blood pressure in response to thiazide diuretics. *Hypertens Res* 2022;45:464-73. (IF: 5.525)

53. ²Huang CC*, Niu DM, Charng MJ*. Genetic Analysis in a Taiwanese Cohort of 750 Index Patients with Clinically Diagnosed Familial Hypercholesterolemia. *J Atheroscler Thromb* 2022;29:639-53. (IF: 4.399)
54. ^{2,5}Huang CJ, Wang WT, Sung SH, Chen CH, Lip GYH, Cheng HM*, Chiang CE*. Revisiting 'intensive' blood glucose control: A causal directed acyclic graph-guided systematic review of randomized controlled trials. *Diabetes Obes Metab* 2022;24: 2341-52. (IF: 6.408)
55. ^{2,5}Huang HT, Huang JL, Lin PL, Lee YH, Hsu CY, Chung FP, Liao CT, Chiou WR, Lin WY, Liang HW, Chang HY*. Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy. *ESC Heart Fail* 2022;9:3825-35. (IF:3.612)
56. ^{2,5}Huang PH, Huang CC*, Lin SJ, Chen JW. Prediction of atrial fibrillation in patients with hypertension: A comprehensive comparison of office and ambulatory blood pressure measurements. *J Clin Hypertens* 2022;24:838-47. (IF: 2.885)
57. ^{2,5}Huang PH, Lu YW, Tsai YL, Wu YW, Li HY, Chang HY, Wu CH, Yang CY, Tarng DC, Huang CC, Ho LT, Lin CF, Chien SC, Wu YJ, Yeh HI, Pan WH, Li YH*; expert committee for the Taiwan Lipid Guidelines for Primary Prevention. 2022 Taiwan lipid guidelines for primary prevention. *J Formos Med Assoc* 2022;121:2393-407. (IF:3.871)
58. ^{2,5}Huang SH, Liao CF, Chen ZY, Chao TF, Chen SA, Tsao HM*. Distinct atrial remodeling in patients with subclinical atrial fibrillation: Lessons from computed tomographic images. *Pharmacol Res Perspect* 2022; 10:e00927. (IF: 2.963)
59. ^{1,5}Huang SY, Lu YY, Lin YK*, Chen YC, Chen YA, Chung CC, Lin WS*, Chen SA, Chen YJ. Ceramide modulates electrophysiological characteristics and oxidative stress of pulmonary vein cardiomyocytes. *Eur J Clin Invest* 2022;52:e13690. (IF: 5.722)
60. ²Huang WC, Lin YH, Wu VC, Chen CH, Siddique S, Chia YC, Tay JC, Sogunuru G, Cheng HM*, Kario K. Who should be screened for primary aldosteronism? A comprehensive review of current evidence. *J Clin Hypertens* 2022;24:1194-203. (IF: 2.885)
61. ²Huang WM, Chang HC, Lee CW, Huang CJ, Yu WC, Cheng HM, Guo CY, Chiang CE, Chen CH, Sung SH*. Impaired renal function and mortalities in acute heart failure with different phenotypes. *ESC Heart Fail* 2022;9:2928-36. (IF:3.612)
62. ²Huang WM, Chen CN, Chen YH, Yen JH, Tseng TY, Cheng HM, Yu WC, Chen CH, Sung SH*. The feasibility and safety of stepwise protocol in cardiopulmonary exercise testing-exercise stress echocardiography for subjects with heart failure. *J Chin Med Assoc* 2022;85:815-20. (IF:3.396)
63. ^{2,5}Huang WP, Chen CY, Lin TW, Kuo CS, Huang HL*, Huang PH*, Lin SJ. Fibroblast growth factor 21 reverses high-fat diet-induced impairment of vascular function via the anti-oxidative pathway in ApoE knockout mice. *J Cell Mol Med* 2022;26:2451-61. (IF: 5.295)
64. ²Hung PF*, Chung FP*, Hung CL, Lin YJ, Kuo TT, Liao JN, Chen YY, Pan CH, Shaw KP, Chen SA. Decreased Expression of Plakophilin-2 and alpha T-Catenin in Arrhythmogenic Right Ventricular Cardiomyopathy: Potential Markers for Diagnosis. *Int J Mol Sci* 2022;23:5529. (IF:6.208)
65. ^{2,5}Hung YH, Huang CC*, Lin LY, Chen JW. Uric Acid and Impairment of Renal Function in Non-diabetic Hypertensive Patients. *Front Med* 2022;8:746886. (IF:5.058)
66. ^{2,5}Jang SJ, Chen YH, Shen TC*. Pitfalls in recapture or repositioning of Evolut system using cusp overlap technique. *Eur Heart J* 2022;43:1684. (IF: 35.855)

67. ^{2,5}Kao PH, Chung FP*, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chao TF, Liao JN, Lin CY, Chang TY, Kuo L, Wu CI, Liu CM, Liu SH, Cheng WH, Lin L, Ton AKN, Hsu CY, Chhay C, Chen SA. Application of Ensite (TM) LiveView function for identification of scar-related ventricular tachycardia isthmus. *J Cardiovasc Electrophysiol* 2022;33:1223-33. (IF: 2.942)
68. ^{2,5}Kao TW, Huang CC*. Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases. *Int J Mol Sci* 2022;23:804. (IF: 6.208)
69. ^{2,5}Kuo CH, Chang TI, Chen CH, Chen CY, Hsieh HL, Hsu SC, Cheng HS, Sue YM, Chen TH, Hsu YH, Lin FY, Shih CM, Huang PH, Liu CT*. Luminal pressure gradient and risk of arteriovenous fistula nonmaturation. *Medicine (Baltimore)* 2022;101:e30835. (IF:1.817)
70. ^{2,4}Kuo CP, Tsai MT, Lee KH, Lin YP, Huang SS, Huang CC, Tseng WC*, Tarng DC*. Dose-response effects of physical activity on all-cause mortality and major cardiorenal outcomes in chronic kidney disease. *Eur J Prev Cardiol* 2022;29:452-61. (IF:8.526)
71. ^{2,4}Kuo CS, Chen CY, Huang HL*, Tsai HY, Chou RH, Wei JH, Huang PH*, Lin SJ. Melatonin Improves Ischemia-Induced Circulation Recovery Impairment in Mice with Streptozotocin-Induced Diabetes by Improving the Endothelial Progenitor Cells Functioning. *Int J Mol Sci* 2022;23:9839. (IF: 6.208)
72. ^{2,5}Kuo FY, Lee CH, Lan WR, Su CH, Lee WL, Wang YC, Lin WS, Chu PH, Lu TM, Lo PH, Tsukiyama S, Yang WC, Cheng LC, Huang CL*, Yin WH, Liu PY*. Effect of CYP2C19 status platelet reactivity in Taiwanese acute coronary syndrome patients switching to prasugrel form clopidogrel: Switch Study. *J Formos Med Assoc* 2022;121:1786-97. (IF:3.871)
73. ²Kuo MJ, Lo LW*, Lin YJ, Chang SL, Hu YF, Chung FP, Tuan TC, Chao TF, Liao JN, Chang TY, Lin CY, Kuo L, Wu CI, Liu CM, Cheng WH, Liu SH, Ton AKN, Chhay C, Kao PH, Chen WT, Hsu CY, Kim S, Chen SA. Low voltage zones detected by omnipolar Vmax map accurately identifies the potential atrial substrate and predicts the AF ablation outcome after PV isolation. *Int J Cardiol* 2022;351:42-7. (IF: 4.039)
74. ^{2,5}Lee CY, Lin SJ, Wu TC*. miR-548j-5p regulates angiogenesis in peripheral artery disease. *Sci Rep* 2022; 12:838. (IF: 4.997)
75. ²Lee HW, Huang CC*, Leu HB, Lin YJ. Comparative efficacy of generic nifedipine versus brand-name amlodipine for hypertension management in Taiwan. *J Clin Hypertens* 2022;24:870-7. (IF: 2.885)
76. ^{2,5}Lee YH, Chiou WR, Hsu CY, Lin PL, Liang HW, Chung FP, Liao CT, Lin WY, Chang HY*. Different left ventricular remodelling patterns and clinical outcomes between non-ischaemic and ischaemic aetiologies in heart failure patients receiving sacubitril/valsartan treatment. *Eur Heart J-Cardiovasc Pharmacother* 2022;8:118-29. (IF: 11.177)
77. ^{2,5}Lee YH, Tsai TH, Chen JH, Huang CJ, Chiang CE, Chen CH, Cheng HM*. Machine learning of treadmill exercise test to improve selection for testing for coronary artery disease. *Atherosclerosis* 2022;340:23-7. (IF: 6.851)
78. ^{2,5}Li CH, Lo LW*, Jain A, Hsieh YC, Lin YJ, Chang SL, Chung FP*, Hu YF, Chao TF, Liao JN, Chang TY, Lin CY, Lugtu IC, Ton ANK, Liu SH, Cheng WH, Liu CM, Wu CI, Chen SA*. Patterns and Characteristics of SKYLINE-Lumipoint Feature in the Catheter Ablation of Atypical Atrial Flutter: Insight from a Novel Lumipoint Module of Rhythmia Mapping System. *J Pers Med* 2022;12:1102. (IF: 3.508)
79. ²Li GY, Chung FP*, Chao TF, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chang

- TY, Kuo L, Wu CI, Liu CM, Liu SH, Cheng WH, Chen SA. Sinus Node Dysfunction after Successful Atrial Flutter Ablation during Follow-Up: Clinical Characteristics and Predictors. *J Clin Med* 2022;11:3212. (IF:4.964)
80. ²Li GY, Lee CC, Huang CC*. Acute Polyserositis with Cardiac Tamponade and Bilateral Refractory Pleural Effusion after ChAdOx1 nCoV-19 Vaccination. *Vaccines* 2022;10:1286. (IF: 4.961)
81. ²Liao JN, Chan YH, Kuo L, Tsai CT, Lim SS, Chao TF*. Optimal anticoagulation in elderly patients with atrial fibrillation: Which drug at which dose? *Kardiol Pol* 2022;80:128-36. (IF: 3.710)
82. ²Liao JN, Chan YH, Kuo L, Tsai CT, Lim SS, Chao TF*. Risk of Ischemic Bowel Disease in Patients With Atrial Fibrillation Receiving Warfarin or Non-vitamin K Antagonist Oral Anticoagulants. *Front Cardiovasc Med* 2022;9:874460. (IF:5.848)
83. ²Liao JN, Chao TF*. Dealing with the High Bleeding and Thrombosis Risks in Critically Ill Patients with Chronic Liver Disease: A Dilemma in the Clinical Practice. *Thromb Haemost* 2022;122: 867-9. (IF: 6.830)
84. ²Liao JN, Kuo L, Liu CM, Chen SA, Chao TF*. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with advanced chronic kidney and liver diseases. *Eur Heart J Suppl* 2022;24(Suppl A):A11-8. (IF: 1.624)
85. ²Liao JN, Lim SS, Chen TJ, Tuan TC, Chen SA, Chao TF*. Modified Taiwan Atrial Fibrillation Score for the Prediction of Incident Atrial Fibrillation. *Front. Cardiovasc Med* 2022;8:805399. (IF: 5.848)
86. ²Liao TWE, Lo LW*, Lin YJ, Chang SL, Hu YF, Chung FP, Chao TF, Liao JN, Yang HW, Lo MT, Chen SA. Nonlinear Heart Rate Dynamics Before and After Paroxysmal Atrial Fibrillation Events. *Acta Cardiol Sin* 2022;38:594-600. (IF: 1.800)
87. ²Lim SS, Huang CC, Hsu PF, Lin CC, Wang YJ, Ding YZ, Liou TL, Wang YW, Huang SS, Lu TM, Chen JW, Chan WL, Lin SJ, Leu HB*. Prolonged sitting time links to subclinical atherosclerosis. *J Chin Med Assoc* 2022;85:51-8. (IF:3.396)
88. ²Lim SS, Kuo L, Chang FP, Chang CC, Yu WC*. Prompt diagnosis of a wild-type transthyretin cardiac amyloidosis: Role of multimodality imaging. *J Chin Med Assoc* 2022;85:1101-5. (IF: 3.396)
89. ²Lin HJ, Pan HY, Chen CH, Cheng HM, Chia YC, Sogunuru GP, Tay JC, Turana Y, Verma N, Kario K, Wang TD*. Standardized home blood pressure monitoring: Rationale behind the 722 protocol. *J Clin Hypertens* 2022;24:1161-73. (IF: 2.885)
90. ^{2,5}Lin JC, Li CH, Chen YY, Weng CJ, Chien YS, Wu SJ, Lo CP, Tien HC, Lin CH, Huang JL, Lin YJ, Hsieh YC*, Chen SA. Rhythm Control Better Prevents Dementia than Rate Control Strategies in Patients with Atrial Fibrillation-A Nationwide Cohort Study. *J Pers Med* 2022;12:572. (IF: 3.508)
91. ^{1,5}Lin SI, Huang CC, Sung SH, Liu LYM, Lin PL, Lan WR, Chao CL, Chiou WR, Tsai CT, Wu YJ, Wang TD, Lee YH*. Preprocedural features of patients under antihypertensive drugs may help identify responders to renal denervation: a hypothesis-generating study. *Rev Cardiovasc Med* 2022;23:65. (IF: 4.430)
92. ^{1,5}Lin SP, Chen CM, Wang KL, Wu KL, Li SC*. Association of Dietary Fish and n-3 Unsaturated Fatty Acid Consumption with Diabetic Nephropathy from a District Hospital in

- Northern Taiwan. *Nutrients* 2022; 14:2148. (IF: 6.706)
93. ^{2,5}Lin WL, Lai CT, Yamada S, Liu SH, Cheng WH, Chou YH, Yang CCH, Kuo TBJ*, Chen SA, Lo LW*. Effects of renal denervation on sleep apnea and arrhythmia in rats with myocardial infarction. *Sleep Med* 2022;91:115-23. (IF: 4.842)
 94. ^{2,5}Lin WQ*, Chattranukulchai P, Lee AP, Lin YH, Yu WC, Liew HB, Oomman A. Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia. *Clin Cardiol* 2022;45:898-907. (IF: 3.287)
 95. ²Liou YJ, Chen MH, Hsu JW, Huang KL, Huang PH*, Bai YM*. Levels of Circulating endothelial progenitor cell dysfunction in patients with bipolar disorder. *Eur Arch Psych Clin Neurosci* 2022; doi: 10.1007/s00406-022-01530-5. (IF:5.760)
 96. ^{1,5}Liu CH, Chen YC, Lu YY, Lin YK, Higa S, Chen SA*, Chen YJ*. Gender Difference in Lithium- Induced Sodium Current Dysregulation and Ventricular Arrhythmogenesis in Right Ventricular Outflow Tract Cardiomyocytes. *Biomedicines* 2022;10:2727. (IF: 4.757)
 97. ^{2,5}Liu CH, Lo LW*, Chung FP, Chang SL, Hu YF, Lin EJ, Huang SC, Gan ST, Lin CY, Chao ZF, Liao ON, Tuan TC, Liu CM, Shiu YC, Wu C, Kuo L, Vicera JJB, Lugtu I, Li CH, Hsieh YC, Chen YJ, Chen SA. The impact of height on recurrence after index catheter ablation of paroxysmal atrial fibrillation. *J Interv Card Electrophysiol* 2022;64:587-95. (IF: 1.759)
 98. ²Liu CM, Hsieh ME, Hu YF*, Wei TY, Wu IC, Chen PF, Lin YJ, Higa S, Yagi N, Chen SA, Tseng VS*. Artificial Intelligence-Enabled Model for Early Detection of Left Ventricular Hypertrophy and Mortality Prediction in Young to Middle-Aged Adults. *Circ-Cardiovasc Qual Outcomes* 2022;15: e008360. (IF: 8.271)
 99. ²Liu CM, Liu CL, Hu KW, Tseng VS, Chang SL, Lin YJ, Lo LW, Chung FP, Chao TF, Tuan TC, Liao JN, Lin CY, Chang TY, Fann CSJ, Higa S, Yagi N, Hu YF*, Chen SA*. A Deep Learning-Enabled Electrocardiogram Model for the Identification of a Rare Inherited Arrhythmia: Brugada Syndrome. *Can J Cardiol* 2022;38:152-9. (IF: 6.617)
 100. ^{2,5}Liu CT, Hsu SC, Hsieh HL, Chen CH, Chen CY, Sue YM, Chen TH, Hsu YH, Lin FY, Shih CM, Shiu YT*, Huang PH*. Inhibition of beta-catenin signaling attenuates arteriovenous fistula thickening in mice by suppressing myofibroblasts. *Mol Med* 2022;28:7. (IF: 6.382)
 101. ^{2,4}Lu DY, Huang WM, Wang WT, Hung SC, Sung SH, Chen CH, Yang YJ, Niu DM, Yu WC*. Reduced global longitudinal strain as a marker for early detection of Fabry cardiomyopathy. *Eur Heart J-Cardiovasc Imaging* 2022;23:487-95. (IF: 9.130)
 102. ²Lu YW, Chang CC*, Chou RH, Tsai YL, Liu LK, Chen LK, Huang PH, Lin SJ. Sex difference in the association between pathological albuminuria and subclinical atherosclerosis: insights from the I-Lan longitudinal aging study. *Aging-US* 2022;14:8001-12. (IF: 5.955)
 103. ^{1,5}Lu YY, Cheng CC, Huang SY, Chen YC, Kao YH, Lin YK, Higa S, Chen SA, Chen YJ*. Fibroblast Growth Factor 1 Reduces Pulmonary Vein and Atrium Arrhythmogenesis via Modification of Oxidative Stress and Sodium/Calcium Homeostasis. *Front Cardiovasc Med* 2022;8:813589. (IF:5.848)
 104. ^{1,5}Lu YY, Lin FJ, Chen YC, Kao YH, Higa S, Chen SA*, Chen YJ*. Role of Endothelin-1 in Right Atrial Arrhythmogenesis in Rabbits with Monocrotaline-Induced Pulmonary Arterial Hypertension. *Int J Mol Sci* 2022;23:10993. (IF:6.208)
 105. ^{2,5}Lugtu IC, Cheng WH, Chang SL, Liu SH, Lo LW*, Chen SA. Percutaneous Left Atrial

- Appendage Closure Using an Occluder Device: A Single Center Experience. *Acta Cardiol Sin* 2022;38:352-61. (IF: 1.800)
106. ^{1,5}Markman TM, John L, Kalluri AG, Tzou WS, Badertscher P, Winterfield J, Partington SL, Santangeli P, Chung FP*. Catheter Ablation of Ventricular Arrhythmias With Indirect Evidence of Critical Substrate Elements Protected by Prosthetic Material. *JACC-Clin Electrophysiol* 2022;8:677-9. (IF:6.124)
 107. ^{1,5}Niu YL, Mayr NP, Chen YH, Chang HH, Wang SP, Lin HY, Pai CC*. Successful Urgent TAVI for Critical Aortic Valve Stenosis after ECMO Implantation. *Med Lith* 2022;58:356. (IF: 2.948)
 108. ^{2,5}Solomon SD*, McMurray JJV, Claggett, Bde Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Honorio JWC, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderang U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. *N Engl J Med* 2022;387:1089-1098. (IF:176.082)
 109. ^{2,5}Solomon SD*, Vaduganathan M, Claggett BL, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Gamba MAA, Al Habeeb W, Han YL, Honorio JWC, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vardeny O, Verma S, Vinh PN, Wilderang U, Zaozerska N, Lindholm D, Petersson M, McMurray JJV. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. *JACC-Heart Fail* 2022;10:184-97. (IF:12.544)
 110. ^{2,5}Sundaram V*, Nagai T, Chiang CE, Reddy YNV, Chao TF, Zakeri R, Bloom C, Nakai M, Nishimura K, Hung CL, Miyamoto Y, Yasuda S, Banerjee A, Anzai T, Simon DI, Rajagopalan S, Cleland JGF, Sahadevan J*, Quint JK. Hospitalization for Heart Failure in the United States, UK, Taiwan, and Japan: An International Comparison of Administrative Health Records on 413,385 Individual Patients. *J Card Fail* 2022;28:353-66. (IF: 6.592)
 111. ²Sung WT, Lo LW*, Lin YJ, Chang SL, Hu YF, Chung FP, Liao JN, Tuan TC, Chao TF, Lin CY, Chang TY, Kuo L, Liu CM, Liu SH, Cheng WH, Ton AKN, Hsu CY, Chhay C, Elimam M, Kuo MJ, Kao PH, Chen WT, Chen SA. Alteration of Skin Sympathetic Nerve Activity after Pulmonary Vein Isolation in Patients with Paroxysmal Atrial Fibrillation. *J Pers Med* 2022;12:1286. (IF:3.508)
 112. ^{2,5}Tang CY, Lai CC, Huang PH, Yang AH, Chiang SC, Huang PC, Tseng KW, Huang CH*. Magnolol reduces myocardial injury induced by renal ischemia and reperfusion. *J Chin Med Assoc* 2022;85:584-96. (IF: 3.396)
 113. ^{2,5}Teng HI, Chen HY, Tsai CT, Huang WC, Chen YY, Hsueh CH, Hau WK, Lu TM*. The clinical impact of serum 1,5-anhydro-D-glucitol levels on coronary artery calcification and adverse outcomes assessed by coronary optical coherence tomography in diabetic patients. *Front Cardiovasc Med* 2022; 9: 997649. (IF:5.848)
 114. ^{2,5}Ton ANK, Liu SH, Lo LW*, Khac TCN, Chou YH, Cheng WH, Lin WL, Peng TY, Lin PY,

- Chang SL, Chen SA. Renal artery denervation prevents ventricular arrhythmias in long QT rabbit models. *Sci Rep* 2022; 12:2904. (IF: 4.997)
115. ²Tsai CT, Chang HH, Leu HB, Ling K, Chen IM, Chen PL, Lin SM, Chen YH*. Technical Characteristics and Feasibility of Coronary Angiography and Percutaneous Coronary Interventions Performed after Transcatheter Aortic Valve Replacement with Self-Expanding Valves. *Acta Cardiol Sin* 2022;38:56-63. (IF: 1.800)
 116. ²Tsai CT, Huang WC, Lu YW, Teng H, Huang SS, Tsai YL, Lee WL, Lu TM*. Obesity paradox in patients with chronic total occlusion of coronary artery. *Eur J Clin Invest* 2022;52:e13698. (IF: 5.722)
 117. ^{2,4}Tsai HC, Ou SM, Wu CC, Huang CC, Hsieh JT, Tseng PY, Lee CY*, Yang CY, Tarng DC. Pentraxin 3 Predicts Arteriovenous Fistula Functional Patency Loss and Mortality in Chronic Hemodialysis Patients. *Am J Nephrol* 2022;53:148-56. (IF:4.605)
 118. ²Tsai TY, Hsu PF*, Wu CH, Huang SS, Chan WL, Lin SJ, Chen JW, Lu TM, Leu HB. Association between Coronary Artery Plaque Progression and Liver Fibrosis Biomarkers in Population with Low Calcium Scores. *Nutrients* 2022;14:3163. (IF: 6.706)
 119. ²Tsai TY, Leu HB, Hsu PF, Yang YL, Chen SC, Huang SS, Chan WL, Lin SJ, Chen JW, Pan JP, Charng MJ, Chen YH, Wu TC, Lu TM, Huang PH, Cheng HM, Huang CC, Sung SH, Lin YJ, Wu CH*. Association between visit-to-visit blood pressure variability and adverse events in coronary artery disease patients after coronary intervention. *J Clin Hypertens* 2022; 24:1327-338. (IF: 2.885)
 120. ^{2,5}Tsai YC, Tsao YP, Huang CJ, Tai YH, Su YC, Chiang CE, Sung SH, Chen CH, Cheng HM*. Effectiveness of salt substitute on cardiovascular outcomes: A systematic review and meta-analysis. *J Clin Hypertens* 2022;24:1147-60. (IF: 2.885)
 121. ^{2,4}Tsai YL, Chou RH, Lu YW, Chang CC, Kuo CS, Huang PH*, Chen JW, Lin SJ. Associations between galectin-1, left ventricular diastolic dysfunction, and heart failure with preserved ejection fraction. *J Cardiol* 2022;79:371-5. (IF: 3.115)
 122. ²Tseng CH, Huang WM*, Yu WC, Cheng HM, Chang HC, Hsu PF, Chiang CE, Chen CH, Sung SH*. The fibrosis-4 score is associated with long-term mortality in different phenotypes of acute heart failure. *Eur J Clin Invest* 2022;52:e13856. (IF:5.722)
 123. ^{1,5}Tung R, Xue YM, Chen ML, Jiang CY, Shatz DY, Besser S, Hu HD, Chung FP, Nakahara S, Kim YH, Satomi K, Shen LS, Liang EP, Liao HT, Gu K, Jiang RH, Jiang J, Hori Y, Choi JI, Ueda A, Komatsu Y, Kazawa S, Soejima K, Chen SA, Nogami A, Yao Y*. First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial. *Circulation* 2022;145:1839-49. (IF:39.922)
 124. ^{1,5}van Geuns RJ*, Chang CC, McEntegart MB, Merkulov E, Kretov E, Lesiak M, O'Kane P, Hanratty CG, Bressollette E, Silvestri M, Wlodarczak A, Barragan P, Anderson R, Protopopov A, Peace A, Menown I, Rocchiccioli P, Onuma Y, Oldroyd KG. Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial. *EuroIntervention* 2022; 17:1467-76. (IF:7.728)
 125. ^{2,5}Wang CY, Hung GU, Lo HC, Tsai SC, He Z, Zhang XW, Chiang KF, Zou JG, Zhou WH, Huang JL*, Chen SA. Clinical impacts of scar reduction on gated myocardial perfusion

- SPECT after cardiac resynchronization therapy. *J Nucl Cardiol* 2022;29:2571-9. (IF:3.872)
126. ^{2,5}Wang SC, Wang XY, Liu CT, Chou RH, Chen ZB*, Huang PH*, Lin SJ. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates Endothelial Inflammation and Microvascular Thrombosis in a Sepsis Mouse Model. *Int J Mol Sci* 2022;23:3065. (IF:6.208)
 127. ^{2,5}Wang TD*, Chiang CE, Chao TH, Cheng HM, Wu YW, Wu YJ, Lin YH, Chen MYC, Ueng KC, Chang WT, Lee YH, Wang YC, Chu PH, Chao TF, Kao HL, Hou CLY, Lin TH 2022 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension. *Acta Cardiol Sin* 2022;38:225-325. (IF:1.800)
 128. ^{2,5}Wen YW, Wang IT, Hu YT, Cheng HM, Cheng KW, Shiu MN*, Tsa YW*. Duration of varenicline prescription and efficacy of smoking cessation treatment: an observational study in Taiwan. *Prev Med* 2022;161:107091. (IF:4.637)
 129. ²Wu CI, Lin YJ*, Lee IH, Lo MT, Hsieh YC, Chen AYY, Wang WK, Chang SL, Lo LW, Hu YF, Chung FP, Tuan TC, Chao TF, Liao JN, Hsieh WH, Chang TY, Lin CY, Feng AN, How CK, Chen SA*. Using QRS loop descriptors to characterize the risk of sudden cardiac death in patients with structurally normal hearts. *PLoS One* 2022;17:e0263894. (IF:3.752)
 130. ^{2,5}Wu HP, Jan SL, Chang SL, Huang CC, Lin MJ*. Correlation Between Smoking Paradox and Heart Rhythm Outcomes in Patients With Coronary Artery Disease Receiving Percutaneous Coronary Intervention. *Front Cardiovasc Med* 2022;9:803650. (IF:5.848)
 131. ^{2,5}Wu SJ, Cheng YT, Li CH, Weng CJ, Hsieh YC*, Chen SA. Leadless Pacemaker Implantation in a Patient with Dextrocardia and Situs Inversus: Tips and Tricks. *Acta Cardiol Sin* 2022;38:103-5. (IF:1.800)
 132. ^{2,5}Wu SJ, Li CH*, Weng CJ, Lin JC, Chien YS, Chen YH, Lin CH, Hsieh YC*, Huang JL, Lo LW, Lin YJ, Chen SA. Efficacy of Cryoballoon Ablation for Atrial Fibrillation and Recurrence Predictors in an Asian Cohort. *J Pers Med* 2022;12:732. (IF:3.508)
 133. ²Wu TC, Chang WH, Lu HY, Shih CC*. Tolvaptan reduces angiotensin II-induced experimental abdominal aortic aneurysm and dissection. *Vasc Pharmacol* 2022;144:106973. (IF:5.738)
 134. ^{2,5}Yang SF, Li SY*, Lin FY, Hsieh SH, Huang PH, Lin SO. Chronic Kidney Disease Is Associated With Increased Cardiac Corin Expression But Decreased Proatrial Natriuretic Peptide Conversion Activity. *J Am Heart Assoc* 2022;11:e025208. (IF:6.107)
 135. ^{2,5}Yang SM, Huang CJ, Chen CH, Yu WC, Sung SH, Guo CY, Chuang SY, Cheng HM*, Chiang CE*. Network meta-analysis and trial sequential analysis for atrial fibrillation patients receiving PCI or with ACS. *J Chin Med Assoc* 2022;85:59-66. (IF:3.396)
 136. ^{2,5}Yavarimanesh M, Cheng HM, Chen CH, Sung SH, Mahajan A, Chaer RA, Shroff SG, Hahn JO, Mukkamala R*. Abdominal aortic aneurysm monitoring via arterial waveform analysis: towards a convenient point-of-care device. *NPJ Digit Med* 2022;5:168. (IF:15.357)
 137. ^{1,5}Yeh CF, Cheng SH, Lin YS, Shentu TP, Huang RT, Zhu JY, Chen YT, Kumar S, Lin MS, Kao HL, Huang PH, Rosello-Sastre E, Garcia F, Jo H, Fang Y*, Yang KC*. Targeting mechanosensitive endothelial TXNDC5 to stabilize eNOS and reduce atherosclerosis in vivo. *Sci Adv* 2022; 8:eabl8096. (IF:14.980)
 138. ^{2,5}Yugo D, Chen YY, Lin YJ*, Chien KL, Chang SL, Lo LW, Hu YF, Chao TF, Chung FP, Liao JN, Chang TY, Lin CY, Tuan TC, Kuo L, Wu CI, Liu CM, Liu SH, Li CH, Hsieh YC*, Chen

- SA. Long-term mortality and cardiovascular outcomes in patients with atrial flutter after catheter ablation. *Europace* 2022; 24:970-8. (IF:5.486)
139. ^{2,5}Yugo D, Kuo MJ, Hu YF*, Liu CM, Lin YJ, Chang SL, Lo LW, Chao TF, Chung FP, Liao JN, Chang TY, Lin CY, Tuan TC, Kuo L, Liu SH, Ton ANK, Chhay C, Elimam A, Chen SA. Dynamic changes in signal-averaged P wave after catheter ablation of atrial fibrillation. *J Chin Med Assoc* 2022;85:549-53. (IF:3.396)
140. ^{2,5}Zhang YQ*, Miao HH, Chia YC, Buranakitjaroen P, Siddique S, Shin J, Turana Y, Park S, Tsoi K, Chen CH, Cheng HM, Li Y, Minh HV, Nagai M, Nailles J, Sison J, Soenarta AA, Sogunuru GP, Sukonthasarn A, Tay JC, Teo BW, Verma N, Wang TD, Hoshide S, Kario K, Wang JG. Cardiovascular risk assessment tools in Asia. *J Clin Hypertens* 2022;24:369-77. (IF:2.885)

Endocrinology and Metabolism

1. ^{2,5}Branch KRH*, Dagenais GR, Avezum A, Basile J, Conget I, Cushman WC, Jansky P, Lakshmanan M, Lanan F, Leiter LA, Pais P, Pogossova N, Raubenheimer PJ, Ryden L, Shaw JE, Sheu WHH, Temelkova-Kurktschiev T, Bethel MA, Gerstein HC, Chinthanie R, Probstfield JL. Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: A post-hoc analysis from the REWIND randomized trial. *Eur J Heart Fail* 2022;24:1805-12. (IF:18.174)
2. ^{2,5}Chan JCN*, Thewjitcharoen Y, Nguyen TK, Tan A, Chia YC, Hwu CM, Jian D, Himathongkam T, Wong KL, Choi YM, Mirasol R, Mohamed M, Kong APS, Ma RCW, Chow EYK, Ozaki R, Lau V, Fu AWC, Hong EG, Yoon KH, Tsang CC, Lau ESH, Lim LL, Luk AOY. Effect of a Web-Based Management Guide on Risk Factors in Patients With Type 2 Diabetes and Diabetic Kidney Disease A JADE Randomized Clinical Trial. *JAMA Netw Open* 2022;5:e223862. (IF:13.353)
3. ^{2,5}Chang LH, Chu CH, Huang CC, Lin LY*. Fibroblast Growth Factor 21 Levels Exhibit the Association With Renal Outcomes in Subjects With Type 2 Diabetes Mellitus. *Front Endocrinol* 2022;13:846018. (IF:6.055)
4. ^{2,5}Chang TT*, Chen C, Lin LY, Chen JW*. CCL4 Deletion Accelerates Wound Healing by Improving Endothelial Cell Functions in Diabetes Mellitus. *Biomedicines* 2022;10:1963. (IF:4.757)
5. Chen WL, Sheu WHH, Li YH, Wang JS, Lee WJ, Liang KW, Lee WL, Lee IT*. Newly diagnosed diabetes based on an oral glucose tolerance test predicts cardiovascular outcomes in patients with coronary artery disease: An observational study. *Medicine (Baltimore)* 2022;101:e29557. (IF:1.817)
6. ^{1,5}Cheng CW, Fang WF, Tang KT, Lin JD*. The pathogenic role of IFN-alpha in thyroiditis mouse models. *Life Sci* 2022;288:120172. (IF:6.780)
7. ^{1,5}Cheng CW, Tang KT, Fang WF, Lee TI, Lin JD*. Differential serum interferon-beta levels in autoimmune thyroid diseases. *Arch Med Sci* 2022;18:1231-40. (IF:3.707)
8. ^{2,5}Cheung JTK, Lau E, Tsui CCT, Siu ELN, Tse NKW, Hui NYL, Ma RCW, Kong APS, Fu A, Lau V, Jia WP, Sheu WHH, Sobrepena L, Yoon KH, Tan ATB, Chia YC, Sosale A, Saboo BD, Kesavadev J, Goh SY, Nguyen TK, Thewjitcharoen Y, Suwita R, Luk AOY, Yang AM, Chow E, Lim LL, Chan JCN*. Combined associations of family history and self-management with age at diagnosis and cardiometabolic risk in 86,931 patients with type 2 diabetes: Joint Asia Diabetes Evaluation (JADE) Register from 11 countries. *BMC Med* 2022;20:249. (IF:11.806)

9. ^{2,5}Chiang DH, Chen CT, Wang TY, Yang YY*, Huang CC, Li TH, Huang SS, Kao SY, Chen CH, Hou MC, Sheu WHH. Enhancing the learning and transfer of preprocedural communication skills during clerkship using audio-visual material: a prospective case-controlled study over 2 years. *BMJ Open* 2022;12:e055953. (IF:3.006)
10. ^{2,5}Chiang DH, Huang CC, Cheng SC, Cheng JC, Wu CH, Huang SS, Yang YY, Yang LY, Kao SY, Chen CH, Shulruf B, Lee FY. Immersive virtual reality (VR) training increases the self-efficacy of in-hospital healthcare providers and patient families regarding tracheostomy-related knowledge and care skills: A prospective pre-post study. *Medicine (Baltimore)* 2022 14;101:e28570. (IF: 1.817)
11. ^{2,5}Cukierman-Yaffe T, Gerstein HC, Basile J, Bethel MA, Cardona-Muñoz EG, Conget I, Dagenais G, Franek E, Hall S, Hancu N, Jansky P, Lakshmanan M, Lanas F, Leiter LA, Lopez-Jaramillo P, Pirags V, Pogossova N, Probstfield J, Rao-Melacini P, Ramasundarahettige C, Raubenheimer PJ, Riddle MC, Rydén L, Shaw JE, Sheu WH, Temelkova-Kurktschiev T. Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial. *J Clin Endocrinol Metab* 2022 14;107:e3448-54. (IF: 6.134)
12. ^{2,5}Gerstein HC*, Ramasundarahettige C, Avezum A, Basile J, Conget I, Cushman WC, Dagenais GR, Franek E, Lakshmanan M, Lanas F, Leiter LA, Pogossova N, Probstfield J, Raubenheimer PJ, Riddle M, Shaw J, Sheu WHH, Temelkova-Kurktschiev T, Turfanda I, Xavier D. A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes. *Cardiovasc Diabetol* 2022;21:158. (IF:8.949)
13. ^{2,5}He KY, Kelly TN, Wang H, Liang J, Zhu L, Cade BE, Assimes TL, Becker LC, Beitelshes AL, Bielak LF, Bress AP, Brody JA, Chang YC, Chang YC, de Vries PS, Duggirala R, Fox ER, Franceschini N, Furniss AL, Gao Y, Guo X, Haessler J, Hung YJ, Hwang SJ, Irvin MR, Kalyani RR, Liu CT, Liu C, Martin LW, Montasser ME, Muntner PM, Mwasongwe S, Naseri T, Palmas W, Reupena MS, Rice KM, Sheu WH, Shimbo D, Smith JA, Snively BM, Yanek LR, Zhao W, Blangero J, Boerwinkle E, Chen YI, Correa A, Cupples LA, Curran JE, Fornage M, He J, Hou L, Kaplan RC, Kardia SLR, Kenny EE, Kooperberg C, Lloyd-Jones D, Loos RJJ, Mathias RA, McGarvey ST, Mitchell BD, North KE, Peyser PA, Psaty BM, Raffield LM, Rao DC, Redline S, Reiner AP, Rich SS, Rotter JJ, Taylor KD, Tracy R, Vasan RS; Samoan Obesity, Lifestyle and Genetic Adaptations Study (OLaGA) Group, NHLBI TOPMed (Trans-Omics for Precision Medicine) (Sheu WH) Consortium, Morrison AC, Levy D, Chakravarti A, Arnett DK, Zhu X. Rare coding variants in RCN3 are associated with blood pressure. *BMC Genomics* 2022 19;23:148. (IF: 4.560)
14. ^{2,5}Hoo CE, Kuo CS, Huang CY, Huang PH, Yang AH, Hsu CP*. Cardiac Dopamine-Secreting Paraganglioma with Involved Skull Base and Retroperitoneum After a History of Pheochromocytoma Post Adrenalectomy. *Int Heart J* 2022;63(4):786-92. (IF:1.823)
15. ^{2,5}Hsu CC, Lin HD, Huang CY, Chiang YL*. Unusual manifestations of adrenal insufficiency A case report of hypopituitarism and Well's syndrome after apoplexy of a silent pituitary gonadotropic adenoma. *Medicine (Baltimore)* 2022;101:e29274. (IF:1.817)
16. ^{2,5}Hsu CY, Sheu WHH, Lee IT*. Brain-Derived Neurotrophic Factor Reduces Long-Term Mortality in Patients With Coronary Artery Disease and Chronic Kidney Disease. *Front Cardiovasc Med* 2022;9:881441. (IF:5.848)
17. Huang CC*, Chung CM, Yang CY, Leu HB, Huang PH, Lin LY, Wu TC, Lin SJ, Pan WH, Chen JW. SLC12A3 Variation and Renal Function in Chinese Patients With Hypertension. *Front Med* 2022;9:863275. (IF:5.058)

18. ^{2,4}Huang SF*, Huang YC, Lee CT, Chou KT, Chen HP, Huang CC, Ji DD, Chan YJ, Yang YY. Cytomegalovirus viral interleukin-10 in patients with Aspergillus infection and effects on clinical outcome. *Mycoses* 2022;65:760-9. (IF:4.931)
19. ^{2,5}Huang WP, Chen CY, Lin TW, Kuo CS, Huang HL*, Huang PH*, Lin SJ. Fibroblast growth factor 21 reverses high-fat diet-induced impairment of vascular function via the anti-oxidative pathway in ApoE knockout mice. *J Cell Mol Med* 2022;26(8):2451-61. (IF:5.295)
20. ^{2,5}Hung YH, Huang CC*, Lin LY, Chen JW. Uric Acid and Impairment of Renal Function in Non-diabetic Hypertensive Patients. *Front Med* 2022;8:746886. (IF:5.058)
21. ^{2,5}Katz DH, Tahir UA, Bick AG, Pampana A, Ngo D, Benson MD, Yu Z, Robbins JM, Chen ZZ, Cruz DE, Deng S, Farrell L, Sinha S, Schmaier AA, Shen D, Gao Y, Hall ME, Correa A, Tracy RP, Durda P, Taylor KD, Liu Y, Johnson WC, Guo X, Yao J, Ida Chen YD, Manichaikul AW, Jain D, Bouchard C, Sarzynski MA, Rich SS, Rotter JI, Wang TJ, Wilson JG, Natarajan P, Gerszten RE; National Heart, Lung, and Blood Institute TOPMed (Trans-Omics for Precision Medicine) (Sheu WH) Consortium†. Whole Genome Sequence Analysis of the Plasma Proteome in Black Adults Provides Novel Insights Into Cardiovascular Disease. *Circulation* 2022;145: 357-70. (IF: 39.918)
22. ²Kuo CS, Chen CY, Huang HL*, Tsai HY, Chou RH, Wei JH, Huang PH*, Lin SJ. Melatonin Improves Ischemia-Induced Circulation Recovery Impairment in Mice with Streptozotocin-Induced Diabetes by Improving the Endothelial Progenitor Cells Functioning. *Int J Mol Sci* 2022;23:9839. (IF:6.208)
23. ^{2,5}Lee WJ, Lin KH, Wang JS, Sheu WHH, Shen CC, Yang CN, Wu SM, Shen LW, Lee SH, Lai DW, Lan KL, Tung CW, Liu SH, Sheu ML*. Aryl hydrocarbon receptor deficiency augments dysregulated microangiogenesis and diabetic retinopathy. *Biomed Pharmacother* 2022;155:113725. (IF:7.419)
24. ^{1,5}Li HY, Sheu WHH*. Updates for hyperglycemia in pregnancy: The ongoing journey for maternal-neonatal health. *J Diabetes Investig* 2022;13:1652-4. (IF:3.681)
25. ^{2,5}Liang JF, Hsu TF, Chen CY, Yang CW, Jean WH, Ou LS, Cheng HM, Huang CC, Yang YY, Chen CH. Developing a competency-based framework for resident-as-teacher. *J Formos Med Asso* 2022;121:1956-62. (IF: 3.817)
26. ^{2,5}Lien ASY, Chiu SYH, Chen SLS, Fann JCY, Yen AMF, Yeh MC, Lou MF, Huang KC, Sheu WHH, Chen HH, Gau BS*. Community-based multiple screening for metabolic syndrome by innovative theory: A longitudinal study. *Public Health Nurs* 2022;39:303-12. (IF:1.770)
27. ^{2,5}Lien CC, Yin WH, Yang DM, Chen LK, Chen CW, Liu SY, Kwok CF, Ho LT, Juan CC*. Endothelin-1 induces lipolysis through activation of the GC/cGMP/Ca²⁺/ERK/CaMKIII pathway in 3T3-L1 adipocytes. *Biochim Biophys Acta Mol Cell Biol Lipids* 2022;1867:159071. (IF:5.228)
28. ^{2,5}Lin CC, Wu MF, Chang YL, Sheu WH, Liou WS. Glycemic control was associated with nonprostate cancer and overall mortalities in diabetic patients with prostate cancer. *J Chin Med Asso* 2022;85:331-40. (IF: 3.396)
29. ^{2,5}Lin CH, Tung YC, Chang TJ, Huang CN*, Hwu CM*. Use of expert consensus to improve the diagnosis and management of type 1 diabetes mellitus. *J Chin Med Assoc* 2022;85:741-6. (IF:3.396)
30. ^{2,5}Lin SY, Huang CC, Yang YY, Huang SF, Lee TY, Li TH, Hou MC, Lin HC. Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice. *PLoS ONE* 2022;17:e0276717. (IF: 3.752)

31. ^{1,5}Lin TR, Huang XY*, Hwu CM. Exercise Experiences of Older Adults with Diabetes and Sarcopenia: A Phenomenological Study. *Clin Nurs Res* 2022;31(2):292-300. (IF:1.724)
32. ^{2,5}Lin YH, Chang HT*, Tseng YH, Chen HS, Chiang SC, Chen TJ, Hwang SJ. Factors related to overweight and obese populations maintaining metabolic health. *PeerJ* 2022;10:e13242. (IF:3.061)
33. ^{2,5}Mahajan A*, Spracklen CN, Zhang WH, Ng MCY, Petty LE,, Sheu WHH,, Boehnke M, Rotter JI, McCarthy MI*, Morris AP*. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. *Nature Genet* 2022;54:560-72. (IF:41.307)
34. ^{2,5}Nakao T, Bick AG, Taub MA, Zekavat SM, Uddin MM,, Hwu CM,, Pankratz N, Ebert BL, Reiner AP, Mathias RA, Do R, Natarajan P*. Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential. *Sci Adv* 2022;8:eab16579. (IF:14.957)
35. ^{1,5}Ramdas S, Judd J, Graham SE, Kanoni S, Wang YX,, Sheu WHH,, Deloukas P, Peloso G, Assimes TL, Willer CJ, Zhu X*, Brown CD*. A multi-layer functional genomic analysis to understand noncoding genetic variation in lipids. *Am J Hum Genet* 2022;109:1366-87. (IF:11.043)
36. ^{2,5}Raubenheimer PJ, Cushman WC, Avezum A, Basile J, Conget I, Dagenais G, Hoover A, Jansky P, Lanas F, Leiter LA, Lopez-Jaramillo P, Pogosova N, Probstfield J, Rao-Melacini P, Rydén L, Sheu WH, Temelkova-Kurktschiev T, C Gerstein H. Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial. *Diab Obes Metab* 2022;24:704-712. (IF: 6.410)
37. ^{2,5}Selvaraj MS, Li XH, Li ZL, Pampana A, Zhang DY, Park J,, Hwu CM,, Rotter JI, Rader DJ, Lin XH, Peloso GM*, Natarajan P*. Whole genome sequence analysis of blood lipid levels in > 66,000 individuals. *Nat Commun* 2022;13:5995. (IF:17.694)
38. ^{2,5}Sheen YJ, Sheu WH, Wang HC, Chen JP, Sun YH, Chen HM. Assessment of diabetic small-fiber neuropathy by using short-wave infrared hyperspectral imaging. *J Biophotonics* 2022;15:e202100220. (IF: 3.390)
39. ¹Sheu WHH, Seino Y, Tan ECH, Yabe D, Ha KH, Nangaku M, Chung WJ, Node K, Yasui A, Lei WY, Lee S, Ustyugova A, Klement R, Deruaz-Luyet A, Kyaw MH, Kim DJ*. Healthcare resource utilization in patients treated with empagliflozin in East Asia. *J Diabetes Investig* 2022;13:810-21. (IF:3.681)
40. ^{2,4}Tsai CT, Lu YW, Chou RH, Kuo CS, Huang PH, Wu CH, Huang SS. Effect of timing of coronary revascularization in patients with post-infectious myocardial infarction. *PLoS One* 2022;17:e0272258. (IF: 3.240)
41. ^{2,5}Tsai JP, Lin DC, Huang WM, Chen M, Chen YH*. Comparison of perinephric fat measurements between malignant and benign renal tumours. *J Int Med Res* 2022;50:3000605221125086. (IF:1.573)
42. ^{2,4}Tsai YL, Chou RH, Lu YW, Chang CC, Kuo CS, Huang PH*, Chen JW, Lin SJ. Associations between galectin-1, left ventricular diastolic dysfunction, and heart failure with preserved ejection fraction. *J Cardiol* 2022;79:371-5. (IF:2.974)
43. ^{2,5}Wainschtein P, Jain D, Zheng Z; TOPMed Anthropometry Working Group; NHLBI TOPMed (Trans-Omics for Precision Medicine) (Sheu WH) Consortium, Cupples LA, Shadyab AH, McKnight B, Shoemaker BM, Mitchell BD, Psaty BM, Kooperberg C, Liu CT, Albert CM, Roden D, Chasman DI, Darbar D, Lloyd-Jones DM, Arnett DK, Regan EA, Boerwinkle E, Rotter JI, O'Connell JR, Yanek LR, de Andrade M, Allison MA, McDonald MN, Chung MK, Fornage M, Chami N, Smith NL, Ellinor PT, Vasani RS, Mathias RA, Loos

- RJF, Rich SS, Lubitz SA, Heckbert SR, Redline S, Guo X, Chen Y-I, Laurie CA, Hernandez RD, McGarvey ST, Goddard ME, Laurie CC, North KE, Lange LA, Weir BS, Yengo L, Yang J, Visscher PM. Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data. *Nature Genetics* 2022;54:263-73. (IF: 41.379)
44. ^{2,5}Wang CY, Huang KC, Lu CW, Chu CH, Huang CN, Chen HS, Lee IT, Chen JF, Chen CC, Chen CS, Hsieh CH, Tien KJ, Chien HY, Huang YY, Hsu JP, Shane GT, Chang AC, Wu YC, Sheu WHH*. A Randomized Controlled Trial of R-Form Verapamil Added to Ongoing Metformin Therapy in Patients with Type 2 Diabetes. *J Clin Endocrinol Metab* 2022;107(10):E4063-71. (IF:6.134)
45. ^{2,5}Wang JS, Chin MC, Chen JF, Huang CN, Hwu CM, Ou HY, Yang YS, Hsu CC*, Wang CY*. Trends in hospitalizations and emergency department visits among women with hyperglycemia in pregnancy between 2008 and 2017 in Taiwan. *Front Endocrinol* 2022;13:1005722. (IF:6.055)
46. ^{2,5}Wang JS, Wu YL, Ou HY, Yang YS, Hsu CC*, Hwu CM*. Trends in all-cause mortality and major causes of death between 2007 and 2018 among patients with diabetes in Taiwan. *Front Endocrinol* 2022;13: 984137. (IF:6.055)
47. ^{2,5}Wu JW, Cheng HM, Huang SS, Liang JF, Huang CC, Shulruf B, Yang YY*, Chen CH*, Hou MC, Sheu WHH. Medical school grades may predict future clinical competence. *J Chin Med Assoc* 2022;85:909-14. (IF:3.396)
48. ^{2,5}Wu JW, Cheng HM, Huang SS, Liang JF, Huang CC, Yang LY, Shulruf B, Yang YY*, Chen CH, Hou MC, Sheu WHH. Comparison of OSCE performance between 6-and 7-year medical school curricula in Taiwan. *BMC Med Educ* 2022;22:15. (IF:3.263)
49. ^{2,5}Wu TE, Chen HS*. The role of growth hormone and IGF-1 in retinopathy: A prospective study of retinopathy in patients with acromegaly and impaired fasting glucose. *Diabetol Metab Syndr* 2022;14:38. (IF:5.395)
50. ^{2,5}Wu TE, Su YW, Chen HS*. Mean HbA1c and HbA1c variability are associated with differing diabetes-related complications in patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract* 2022;192:110069. (IF:8.180)
51. ²Wu TH, Chang LH, Chu CH, Hwu CM, Chen HS, Lin LY*. Soluble tumor necrosis factor receptor 2 is associated with progressive diabetic kidney disease in patients with type 2 diabetes mellitus. *PLoS One* 2022;17:e0266854. (IF:3.752)
52. ²Wu TH, Lee IT, Ho LT, Sheu WHH, Hwu CM*. Combined lipid goal attainment in patients with type 2 diabetes and dyslipidemia: A head-to-head comparative trial of statins. *J Chin Med Assoc* 2022;85:831-8. (IF:3.396)
53. ²Wu TH, Lin YC, Hwu CM*. Ten-year atherosclerotic cardiovascular disease risk prediction for postmenopausal women: Impacts of isolated postchallenge hyperglycemia. *Medicine (Baltimore)* 2022;101:e30352. (IF:1.817)
54. ²Wu TH, Tsai SC, Lin HW, Chen CN, Hwu CM*. Increased serum levels of advanced glycation end products are negatively associated with relative muscle strength in patients with type 2 diabetes mellitus. *BMC Endocr Disord* 2022;22:118. (IF:3.263)
55. ^{2,5}Yang YY, Huang PH, Yang LY, Huang CC, Liu CW, Huang SS, Chen CH, Lee FY, Kao SY, Shulruf B. Equal Z standard-setting method to estimate the minimum number of panelists for a medical school's objective structured clinical examination in Taiwan: a simulation study. *J Educ Eval Health Prof* 2022;19:27. (IF: 0.58)
56. ^{2,5}Yen FS, Hou MC, Wei JC, Shih YH, Hsu CY, Hsu CC, Hwu CM. Liver-related long-term outcomes of alpha-glucosidase inhibitors in patients with diabetes and liver cirrhosis. *Front Pharmacol* 2022;13:1049094. (IF: 5.988)

57. ^{2,5}Yen FS, Hsu CC, Hu KC, Hung YT, Hsu CY, Wei JC, Hwu CM*. Metformin and the Risk of Chronic Urticaria in Patients with Type 2 Diabetes. *Int J Environ Res Public Health* 2022;19:11045. (IF:4.614)
58. ^{2,5}Yen FS, Hsu CC, Shih YH, Pan WL, Wei JCC*, Hwu CM*. Metformin and the Development of Asthma in Patients with Type 2 Diabetes. *Int J Environ Res Public Health* 2022;19:8211. (IF:4.614)
59. ^{2,5}Yen FS, Hsu CC, Wei JCC, Hou MC*, Hwu CM*. Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease. *Front Med* 2022;9:839456. (IF:5.058)
60. ^{2,5}Yen FS, Huang YH, Hou MC, Hwu CM, Lo YR, Shin SJ, Hsu CC*. Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis. *Br J Clin Pharmacol* 2022;88:311-22. (IF:3.716)
61. ^{2,5}Yen FS, Hwu CM*. Similarities and differences in the natural history of youth-onset type 2 diabetes between the West and Asia. *J Diabetes Investig* 2022;13:941-3. (IF:3.681)
62. ^{2,5}Yen FS, Wei JCC, Chiu LT, Hsu CC*, Hwu CM*. Diabetes, hypertension, and cardiovascular disease development. *J Transl Med* 2022;20:9. (IF:8.440)
63. ^{2,5}Yen FS, Wei JCC, Chiu LT, Hsu CC*, Hwu CM*. Cardiovascular outcomes of metformin use in patients with type 2 diabetes and chronic obstructive pulmonary disease. *Front Pharmacol* 2022;13:919881. (IF:5.988)
64. ^{2,5}Yen FS, Wei JCC, Hung YT, Hsu CC*, Hwu CM*. Long-term outcomes of the pay-for-performance program for patients with young-onset (20-40 years of age) type 2 diabetes. *Diabetes Res Clin Pract* 2022;193:110136. (IF:8.180)
65. ^{2,5}Yen FS, Wei JCC, Liu JS, Hsu CC*, Hwu CM*. Clinical course of adolescents with type 2 diabetes mellitus: A nationwide cohort study in Taiwan. *J Diabetes Investig* 2022;13:1905-13. (IF:3.681)
66. ^{2,5}Yen FS, Wei JCC, Shih YH, Hsu CY, Hsu CC*, Hwu CM*. Metformin Use before Influenza Vaccination May Lower the Risks of Influenza and Related Complications. *Vaccines* 2022;10:1752. (IF:4.961)
67. ^{2,5}Yen FS, Wei JCC, Shih YS, Hsu CC*, Hwu CM*. Metformin use and the risk of bacterial pneumonia in patients with type 2 diabetes. *Sci Rep* 2022;12:3270. (IF:4.996)
68. ^{2,5}Yen FS, Wei JCC, Shih YS, Pan WL, Hsu CC*, Hwu CM*. Role of Metformin in Morbidity and Mortality Associated with Urinary Tract Infections in Patients with Type 2 Diabetes. *J Pers Med* 2022;12:702. (IF:3.508)
69. ^{2,3}Yen FS, Wei JCC, Yip HT, Hwu CM*, Hsu CC*. Diabetes, Hypertension, and the Risk of Dementia. *J Alzheimers Dis* 2022;89:323-33. (IF:4.160)
70. ^{2,5}Yen FS, Wei JCC, Yu TS, Hsu C, Hsu CC*, Hwu CM*. Sulfonylurea Use in Patients with Type 2 Diabetes and COPD: A Nationwide Population-Based Cohort Study. *Int J Environ Res Public Health* 2022;19:15013. (IF:4.614)

Infectious Diseases

1. ²Chen IR, Lin SN, Wu XN, Chou SH, Wang FD, Lin YT*. Clinical and Microbiological Characteristics of Bacteremic Pneumonia Caused by *Klebsiella pneumoniae*. *Front Cell Infect Microbiol* 2022;12:903682. (IF:6.073)
2. ^{2,5}Chen WY, Lo YC, Huang PH, Chen YX, Tsao PC, Lee YS, Jeng MJ, Hung MC*. Increased antibiotic exposure in early life is associated with adverse outcomes in very low birth weight

- infants. *J Chin Med Assoc* 2022;85:939-43. (IF:3.396)
3. ^{2,4}Hsieh YC, Wu PS, Lin YT, Huang YH, Hou MC, Lee KC*, Lin HC. (Pro)renin receptor inhibition attenuated liver steatosis, inflammation, and fibrosis in mice with steatohepatitis. *Faseb J* 2022;36:e22526. (IF:5.834)
 4. ²Hsu CH, Chen HP*, Chen PL, Chan YJ. Detection of influenza and non-influenza respiratory viruses in lower respiratory tract specimens among hospitalized adult patients and analysis of the clinical outcome. *J Microbiol Immunol Infect* 2022;55:820-8. (IF:10.273)
 5. ^{2,4}Huang LJ, Chen SJ, Hu YW, Liu CY, Wu PF, Sun SM, Lee SY, Chen YY, Lee CY, Chan YJ, Chou YC, Wang FD*. The impact of antimicrobial stewardship program designed to shorten antibiotics use on the incidence of resistant bacterial infections and mortality. *Sci Rep* 2022;12:913. (IF:4.996)
 6. ²Huang PH, Chen WY, Chou SH, Wang FD, Lin YT*. Risk Factors for the Development of Colistin Resistance during Colistin Treatment of Carbapenem-Resistant *Klebsiella pneumoniae* Infections. *Microbiol Spectr* 2022;10:e0038122. (IF:9.043)
 7. ²Huang SF*, Huang YC, Lee CT, Chou KT, Chen HP, Huang CC, Ji DD, Chan YJ, Yang YY. Cytomegalovirus viral interleukin-10 in patients with *Aspergillus* infection and effects on clinical outcome. *Mycoses* 2022;65:760-9. (IF:4.931)
 8. ²Juan CH, Chou SH, Chen IR, Yang CI, Lin YT*, Chen L. Intestinal colonisation with hypervirulent or third-generation cephalosporin-resistant *Klebsiella pneumoniae* strains upon hospital admission in a general ward in Taiwan. *Int J Antimicrob Agents* 2022;60:106624. (IF:15.441)
 9. ^{2,5}Ko HK, Yu WK, Pan SW, Chen WC, Yang KY, Lin YT, Wang FD, Yang MH*, Chen YM*. Consensus statement and recommendations on the treatment of COVID-19: 2021 update. *J Chin Med Assoc* 2022;85:5-17. (IF:3.396)
 10. ^{2,4}Lee PC, Chang TE, Wang YP, Lee KC, Lin YT, Chiou JJ, Huang CW, Yang UC, Li FY, Huang HC, Wu CY, Huang YH, Hou MC*. Alteration of gut microbial composition associated with the therapeutic efficacy of fecal microbiota transplantation in *Clostridium difficile* infection. *J Formos Med Assoc* 2022;121:1636-46. (IF:3.871)
 11. ^{2,5}Lee YT, Huang TW, Liu IF, Kuo SC, Yang YS, Lin PY, Liu CP, Liu YM, Chen TL, Wang FD, Wang YC*. The prediction values of carbapenemase detection methods and carbapenem susceptibility testing for clinical outcomes of patients with *Acinetobacter* bacteremia under carbapenem treatment. *J Microbiol Immunol Infect* 2022;55:257-65. (IF:10.273)
 12. ^{2,5}Li LH, Lu HF, Liu YF, Lin YT, Yang TC*. FadACB and smeU1VWU2X contribute to oxidative stress-mediated fluoroquinolone resistance in *Stenotrophomonas maltophilia*. *Antimicrob Agents Chemother* 2022;66:e0204321. (IF:5.938)
 13. ^{2,5}Liao CH, Lu HF, Huang HH, Chen Y, Li LH, Lin YT, Yang TC*. The fciTABC and feoABI systems contribute to ferric citrate acquisition in *Stenotrophomonas maltophilia*. *J Biomed Sci* 2022;29:26. (IF:12.771)
 14. ^{2,5}Lin SY, Lu PL, Wu TS, Shie SS, Chang FY, Yang YS, Chiang TT, Wang FD, Ho MW, Chou CH, Liu JW, Shi ZY, Chuang YC, Tang HJ*. Correlation between Cefoperazone/ Sulbactam MIC values and clinical outcomes of *Escherichia coli* bacteremia. *Infect Dis Ther* 2022;11:1853-67. (IF:6.119)
 15. ^{1,5}Liu EYM, Chen JH, Lin JC, Wang CH, Fung CP, Ding YJ, Chang FY, Siu LK*. Cross-

- protection induced by highly conserved outer membrane proteins (Omps) in mice immunized with OmpC of *Salmonella* Typhi or OmpK36 of *Klebsiella pneumoniae*. *Vaccine* 2022;40:2604-11. (IF:4.169)
16. ^{2,5}Liu PY, Ko WC, Lee WS, Lu PL, Chen YH, Cheng SH, Lu MC, Lin CY, Wu TS, Yen MY, Liu CP, Wang LS, Shao PL, Lee YL, Shi ZY, Chen YS, Wang FD, Tseng SH, Lin CN, Chen YH, Sheng WH, Lee CM, Tang HJ, Hsueh PR*. In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible *Pseudomonas aeruginosa* and *Acinetobacter baumannii* isolates associated from bloodstream infection in Taiwan between 2018-2020. *J Microbiol Immunol Infect* 2022;55:888-95. (IF:10.273)
 17. ^{2,5}Pan SW, Shu CC, Lee CC, Feng JY*, Chan YJ, Chen YM, Su WJ*. Role of soluble t-cell immunoglobulin mucin domain-3 in differentiating nontuberculous mycobacterial lung disease from pulmonary colonization. *Arch Bronconeumol* 2022;58:547-53. (IF:6.333)
 18. ^{2,5}Pan SW, Su WJ, Chan YJ, Ho ML, Feng JY*, Shu CC*, Wang JY, Wang HC, Yu CJ, Chen YM. Disease progression in patients with nontuberculous mycobacterial lung disease of nodular bronchiectatic (NB) pattern: The roles of cavitory NB and Soluble Programmed Death Protein-1. *Clin Infect Dis* 2022;75:239-47. (IF:20.999)
 19. ^{2,5}Pan SY, Shih YL, Huang HH, Li LH, Lin YT, Yang TC*. The involvement of PacIRA system of *Stenotrophomonas maltophilia* in the uptake of *Pseudomonas aeruginosa* pyochelin and intraspecies competition for iron acquisition. *J Microbiol Immunol Infect* 2022;55:273-81. (IF:10.273)
 20. ^{2,5}Shih YL, Wu CM, Lu HF, Li LH, Lin YT, Yang TC*. Involvement of the hemP-hemA-smlt0796-smlt0797 Operon in Hemin Acquisition by *Stenotrophomonas maltophilia*. *Microbiol Spectr* 2022;10:e0032122. (IF:9.043)
 21. ^{2,5}Sy CL, Chen PY, Cheng CW, Huang LJ, Wang CH, Chang TH, Chang YC, Chang CJ, Hii IM, Hsu YL, Hu YL, Hung PL, Kuo CY, Lin PC, Liu PY, Lo CL, Lo SH, Ting PJ, Tseng CF, Wang HW, Yang CH, Lee SSJ*, Chen YS, Liu YC, Wang FD. Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms. *J Microbiol Immunol Infect* 2022;55:359-86. (IF:10.273)
 22. ^{2,5}Tsai YT, Lee YL, Lu MC, Shao PL, Lu PL, Cheng SH, Ko WC, Lin CY, Wu TS, Yen MY, Wang LS, Liu CP, Lee WS, Shi ZY, Chen YS, Wang FD, Tseng SH, Lin CN, Chen YH*, Sheng WH, Lee CM, Tang HJ, Lin CY, Chen YH*, Hsueh PR*. Nationwide surveillance of antimicrobial resistance in invasive isolates of *Streptococcus pneumoniae* in Taiwan from 2017 to 2019. *J Microbiol Immunol Infect* 2022;55:215-24. (IF:10.273)
 23. ^{1,5}Wang CY*, Hwang KP, Kuo HK, Peng WJ, Shen YH, Kuo BS, Huang JH, Liu HP, Ho YH, Lin F, Ding S, Liu Z, Wu HT, Huang CT, Lee YJ, Liu MC, Yang YC, Lu PL, Tsai HC, Lee CH, Shi ZY, Liu CE, Liao CH, Chang FY, Chen HC, Wang FD, Hou KL, Cheng J, Wang MS, Yang YT, Chiu HC, Jiang MH, Shih HY, Shen HY, Chang PY, Lan YR, Chen CT, Lin YL, Liang JJ, Liao CC, Chou YC, Morris MK, Hanson CV, Guirakhoo F, Hellerstein M, Yu HJ, King CC, Kemp T, Heppner DG, Monath TP. A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. *J Clin Invest* 2022;132:e157707. (IF:19.456)
 24. ^{1,4}Wang YP, Chen YH, Hung IC, Chu PH, Chang YH, Lin YT, Yang HC*, Wang JT*. Transporter genes and *fosA* associated with Fosfomycin resistance in Carbapenem-resistant

Klebsiella pneumoniae. *Front Microbiol* 2022;13:816806. (IF:6.064)

25. ^{2,5}Wu CJ, Chen Y, Li LH, Wu CM, Lin YT, Ma CH, Yang TC*. Roles of SmeYZ, SbiAB, and SmeDEF Efflux systems in iron homeostasis of *Stenotrophomonas maltophilia*. *Microbiol Spectr* 2022;10:e0244821. (IF:9.043)
26. ^{2,5}Wu CM, Huang HH, Li LH, Lin YT, Yang TC*. Molecular characterization of three tandemly located flagellin genes of *Stenotrophomonas maltophilia*. *Int J Mol Sci* 2022;23:3863. (IF:6.208)
27. ^{1,5}Wu HJ, Yu YF, Ku SWW, Tseng YC, Yuan CW, Li CW, Huang PH, Ko NY, Anderson PL, Strong C*. Usability and effectiveness of adherence monitoring of a mobile app designed to monitor and improve adherence to event-driven and daily HIV pre-exposure prophylaxis among men who have sex with men in Taiwan. *Digit Health* 2022;8: 20552076221102770. (IF:4.687)

Nephology

1. ^{2,4}Chang YA, Tarng DC, Yang CY*. Lentiform fork sign in a uremic patient after inadvertent exposure to metformin. *Clin Toxicol (Phila)* 2022;60:406-7. (IF:3.738)
2. ^{2,5}Chen CF, Lee CY, Chen FA, Yang CY, Chen TH, Ou SM, Lee KH, Li CP, Chan CH, Lee PC, Chen YT, Lee TL, Ho Y, Chen FY, Ma HW, Chen JY, Tan AC*, Li SY*, Lin CC*. Far-infrared therapy improves arteriovenous fistula patency and decreases plasma asymmetric dimethylarginine in patients with advanced diabetic kidney disease: A prospective randomized controlled trial. *J Clin Med* 2022;11:4168. (IF:4.964)
3. ^{2,5}Chen HD, Yu CC, Yang IH, Hung CC, Kuo MC, Tarng DC, Chang JM*, Hwang DY*. UMOD mutations in chronic kidney disease in Taiwan. *Biomedicines* 2022;10:2265. (IF:4.757)
4. ^{2,4}Chen SY, Chu FY*, Yang CY*, Tarng DC. Flumazenil partially reverses gamma-hydroxybutyrate (GHB)-induced coma: a case report. *Am J Drug Alcohol Abuse* 2022;48:629-30. (IF:3.912)
5. ^{2,5}Chen TH, Chu YC, Ou SM*, Tarng DC*. Associations of atrial fibrillation with renal function decline in patients with chronic kidney disease. *Heart* 2022;108:438-44. (IF:7.369)
6. ^{2,4}Chen TH, Ou SM*, Tarng DC*. Associations of high anti-CMV IgG titer with renal function decline and allograft rejection in kidney transplant patients. *J Chin Med Assoc* 2022;85:183-9. (IF:3.396)
7. ²Chen YA, Ou SM*, Lin CC*. Influence of dialysis membranes on clinical outcomes: From History to Innovation. *Membranes* 2022;12:152. (IF:4.562)
8. ^{2,5}Chen YT, Kao ZK, Shih CJ, Ou SM, Yang CY*, Yang AH, Lee OK, Tarng DC. Magnesium exposure increases hip fracture risks in patients with chronic kidney disease: a population-based nested case-control study. *Osteoporos Int* 2022;33:1079-87. (IF:5.071)
9. ^{2,4}Cheng WY, Yang CY*, Tarng DC. Matcha-like ascites. *Ther Apher Dial* 2022;26: 854-5. (IF:2.195)
10. ^{2,5}Chiang MH, Yang CY, Kuo YJ, Cheng CY, Huang SW, Chen YP*. Inverse relationship between mean corpuscular volume and T-Score in chronic dialysis patients. *Medicina (Kaunas)* 2022;58:497. (IF:2.948)

11. ^{2,4}Chou YH, Chen YT, Chen JY, Tarng DC, Lin CC, Li SY*. Baseline peritoneal membrane transport characteristics are associated with peritonitis risk in incident peritoneal dialysis patients. *Membranes (Basel)* 2022;12:276. (IF:4.562)
12. Hsieh MY, Cheng CH, Chen CH, Liao MT, Lin CC, Yang TF, Chuang SY, Wu CC*. The association of long-term blood pressure variability with hemodialysis access thrombosis. *Front Cardiovasc Med* 2022;9:881454. (IF:5.846)
13. ^{2,4}Huang CC*, Chung CM, Yang CY, Leu HB, Huang PH, Lin LY, Wu TC, Lin SJ, Pan WH, Chen JW. SLC12A3 Variation and renal function in Chinese patients with hypertension. *Front Med (Lausanne)* 2022;9:863275. (IF:5.058)
14. ^{2,5}Huang PH, Lu YW, Tsai YL, Wu YW, Li HY, Chang HY, Wu CH, Yang CY, Tarng DC, Huang CC, Ho LT, Lin CF, Chien SC, Wu YJ, Yeh HI, Pan WH, Li YH*; expert committee for the Taiwan Lipid Guidelines for Primary Prevention 2022 Taiwan lipid guidelines for primary prevention. *J Formos Med Assoc* 2022;121:2393-407. (IF:3.871)
15. ^{1,5}Huang WC, Wang MT, Lai TS, Lee KH, Shao SC, Chen CH, Su CH, Chen YT, Sun JM, Chen YC*. Nephrotoxins and acute kidney injury – The Consensus of the Taiwan Acute Kidney Injury Task Force. *J Formos Med Assoc* 2022;121:886-95. (IF:3.282)
16. ^{2,5}Kao TW, Lee KH, Chan WP, Fan KC, Liu CW, Huang YC*. Continuous use of metformin in patients receiving contrast medium: what is the evidence? A systematic review and meta-analysis. *Eur Radiol* 2022;32:3045-55 (IF:5.315)
17. ^{2,5}Kuo CP, Tsai MT, Lee KH, Lin YP, Huang SS, Huang CC, Tseng WC*, Tarng DC*. Dose-response effects of physical activity on all-cause mortality and major cardiorenal outcomes in chronic kidney disease. *Eur J Prev Cardiol* 2022;29:452-61. (IF:8.526)
18. ^{2,5}Kuo KL, Liu JS, Lin MH, Hsu CC*, Tarng DC*; Taiwan Society of Nephrology Renal Registry Data System Research Group. Association of anemia and iron parameters with mortality among prevalent peritoneal dialysis patients in Taiwan: the AIM-PD study. *Sci Rep* 2022;12:1269. (IF:4.997)
19. ^{2,5}Lai YT, Lin CH, Hsieh CC, Yang JC, Tsou HH, Lin CC, Li SY, Chan HL, Liu WS*. Combining Yoga Exercise with Rehabilitation Improves Balance and Depression in Patients with Chronic Stroke: A Controlled Trial. *Appl Sci* 2022;12:922. (IF:2.838)
20. ^{2,5}Lee CT, Lee CC, Wu MJ, Chiu YW, Leu JG, Wu MS, Peng YS, Wu MS*, Tarng DC*. Long-term safety and efficacy of ferric citrate in phosphate-lowering and iron-repletion effects among patients with on hemodialysis: A multicenter, open-label, Phase IV trial. *PLoS One* 2022;17:e0264727. (IF:3.752)
21. ²Lee KH, Chu YC, Tsai MT, Tseng WC, Lin YP, Ou SM*, Tarng DC*. Artificial intelligence for risk prediction of end-stage renal disease in sepsis survivors with chronic kidney disease. *Biomedicine* 2022;10:546. (IF:4.757)
22. ^{2,5}Li MC, Chang PY, Luo HR, Chang LY, Lin CY, Yang CY*, Lee OK, Wu Lee YH, Tarng DC. Functioning tailor-made 3D-printed vascular graft for hemodialysis. *J Vasc Access* 2022:11297298221086173. (IF:2.326)
23. ^{2,5}Liao MT, Luo CM, Hsieh MC, Hsieh MY, Lin CC, Chie WC, Yang TF, Wu CC*. Stent grafts improved patency of ruptured hemodialysis vascular accesses. *Sci Rep* 2022;12:51. (IF:4.996)

24. ^{2,5}Lin CC, Chang TY, Lu YC, Wu YS, Huang W, Lo WC, Liu GF, Hsu WC, Ohashi PS, Mak TW, Fuh JL, Chen HC, Tarng DC*, Chen NJ*. TREM-2 mediates dendritic cell-induced NO to suppress Th17 activation and ameliorate chronic kidney diseases. *J Mol Med (Berl)* 2022;100:917-31. (IF:5.606)
25. ^{2,5}Liu WS, Lin CH, Li SY, Lin CC, Liu TY, Tan AC, Tsou HH*, Chan HL*, Lai YT*. Perfluorooctanesulfonate can cause negative bias in creatinine measurement in hemodialysis patients using polysulfone dialysis membranes. *Membranes* 2022;12:778. (IF:4.562)
26. Niu CY, Yang SF, Ou SM, Wu CH, Huang PH, Hung CL, Lin CC, Li SY*. Sacubitril/Valsartan in patients with heart failure and concomitant end-stage kidney disease. *J Am Heart Assoc* 2022;11:e026407. (IF: 6.107)
27. ²Ou SM, Chao CJ, Tsai MT, Lee KH, Tseng WC, Bin PJ, Lin YP, Hsu CY*, Tarng DC*. Echocardiographic features of left ventricular dysfunction and outcomes in chronic kidney disease. *Heart* 2022;109:134-42. (IF:7.369)
28. ²Ou SM, Lee KH, Tsai MT, Tseng WC, Chu YC*, Tarng DC*. Artificial intelligence for risk prediction of rehospitalization with acute kidney injury in sepsis survivors. *J Pers Med* 2022;12:43. (IF:3.508)
29. ²Ou SM, Lee KH, Tsai MT, Tseng WC, Chu YC*, Tarng DC*. Sepsis and the risks of long-term renal adverse outcomes in patients with chronic kidney disease. *Front Med (Lausanne)* 2022;9:809292. (IF:5.058)
30. ²Ou SM, Tsai MT, Chen HY, Li FA, Lee KH, Tseng WC, Chang FP, Lin YP, Yang RB*, Tarng DC*. Urinary galectin-3 as a novel biomarker for the prediction of renal fibrosis and kidney disease progression. *Biomedicines* 2022;10:585. (IF:4.757)
31. Ramachandran R, Bhargava V, Jasuja S*, Gallieni M, Jha V, Sahay M, Alexender S, Mostafi M, Pisharam JK, Wai TSC, Jacob C, Gunawan A, Leong GB, Thwin KT, Agrawal RK, Vareesangthip K, Tanchanco R, Choong L, Herath C, Lin CC, Cuong NT, Akhtar SF, Alshahow A, Rana DS, Kher V, Rajapurkar MM, Jeyaseelan L, Puri S, Sagar G, Bahl A, Verma S, Sethi A, Vachharajani T. Interventional nephrology and vascular access practice: A perspective from South and Southeast Asia. *J Vasc Access* 2022;23:849-60. (IF:2.326)
32. Tang YS, Tsai YC, Chen TW, Li SY. Artificial kidney engineering: The development of dialysis membranes for blood purification. *Membranes(Basel)* 2022;12:177. (IF:4.562)
33. Tong ZJ, Kuo CW, Yen PC, Lin CC, Tsai MT, Lu SH, Chang YP, Liu WS, Tsou HH, Cheng HW, Wang HT*. Acrolein plays a culprit role in the pathogenesis of diabetic nephropathy in vitro and in vivo. *Eur J Endocrinol* 2022;187:579-92. (IF:6.558)
34. ^{2,4}Tsai CY, Fang TP, Chen SW, Chen HW, Lin EC, Lin TA, Tarng DC, Chang YI*. Di(2-ethylhexyl)phthalate impairs erythropoiesis via inducing Klotho expression and not via bioenergetic reprogramming. *Am J Transl Res* 2022;14:1234-5. (IF:3.94)
35. ^{2,5}Tsai HC, Ou SM, Wu CC, Huang CC, Hsieh JT, Tseng PY, Lee CY, Yang CY*, Tarng DC. Pentraxin 3 predicts arteriovenous fistula functional patency loss and mortality in chronic hemodialysis patients. *Am J Nephrol* 2022;53:148-56. (IF:4.605)
36. ^{2,5}Weng SC, Wen MC, Hsieh SL, Chen NJ*, Tarng DC*. Decoy receptor 3 suppresses T-cell priming and promotes apoptosis of effector T-Cells in acute cell-mediated rejection: The role of reverse signaling. *Front Immunol* 2022;13:879648. (IF:8.787)
37. ²Wu BS, Chu FY, Yang CY*. Water reduces iron toxicity. *Toxicol Ind Health* 2022;38: 773-5.

(IF:1.851)

38. ^{2,4}Wu BS, Wei CH, Yang CY, Lin MH, Hsu CC, Hsu YJ, Lin SH*, Tarng DC*. Mortality rate of end-stage kidney disease patients in Taiwan. *J Formos Med Assoc* 2022;121 Suppl 1:S12-9. (IF:3.871)
39. ^{2,5}Wu CK, Tarng DC, Yang CY, Leu JG, Lin CH*. Factors affecting arteriovenous access patency after percutaneous transluminal angioplasty in chronic haemodialysis patients under vascular access monitoring and surveillance: a single-centre observational study. *BMJ Open* 2022;12:e055763. (IF:3.007)
40. ²Wu TH, Hsieh SC, Li TH, Lu CH, Liao HT, Shen CY, Li KJ, Wu CH, Kuo YM, Tsai CY*, Yu CL*. Molecular basis for paradoxical activities of polymorphonuclear neutrophils in inflammation/anti-inflammation, bactericide/autoimmunity, pro-cancer/anticancer, and antiviral infection/SARS-CoV-II-induced immunothrombotic dysregulation. *Biomedicines* 2022;10:773. (IF:4.757)
41. ²Wu TH, Liao HT, Li TH, Tsai HC, Lin NC, Chen CY, Tsai SF, Huang TH, Tsai CY, Yu CL. High-throughput sequencing of complementarity determining region 3 in the heavy chain of B-cell receptor in renal transplant recipients: A preliminary report. *J Clin Med* 2022;11:2980. (IF:4.964)
42. ²Yang CY*, Wu BS, Wang YF, Wu Lee YH, Tarng DC. Weight-based assessment of access flow threshold to predict arteriovenous fistula functional patency. *Kidney Int Rep* 2022;7:507-15. (IF:6.234)
43. ^{2,5}Yang SF, Li SY*, Lin FY, Hsieh SH, Huang PH*, Lin SO. Chronic kidney disease is associated with increased cardiac corin expression but decreased proatrial natriuretic peptide conversion activity. *J Am Heart Assoc* 2022;11:e025208. (IF:6.106)

Hematology

1. ^{2,5}Chen CF*, Yu YB, Tsai SW, Chiu JW, Hsiao LT, Gau JP, Hsu HC. Total knee replacement for patients with severe hemophilic arthropathy in Taiwan: A nationwide population-based retrospective study. *2022 Feb 1;85(2):228-232.* (IF:3.396)
2. ^{2,5}Hwang WL, Chen TC, Lin HY, Chang MC, Hsiao PC, Bai LY, Kuo CY, Chen YC, Liu TC, **Gau JP**, Wang PN, Hwang WS, Kuo MC, Liu CY, Liu YC, Ma MC, Su NW, Wang CC, Wu YY, Yao M, Yeh SP, Cheng HW, Lee YM, Ku FC, Tang JL*. NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan. *Int J Hematol* 2022;115:704-12. (IF:2.324)
3. ^{2,5}Liu MA, Lee CC, Phung Q, Dao QL, Tehrani B, Yao M, Li CC, Wu KH, Chen TC, Gau JP, Li SS, Wang PN, Liu YC, Wang TF, Chiou LW, Lee MY, Yu MS, Wang CC, Lin SC, Chen YC, Chao TY, Ma MC, Chen CC, Chang HH*. Incidence and predictors of idiopathic pneumonia syndrome in hematopoietic stem cell transplant patients: a nationwide registry study. *Int J Hematol* 2022;116:770-7. (IF:2.324)
4. ²Liu YC, Kwon J, Fabiani E, Xiao Z., Liu YV, Follo MY, Liu J, Huang H, Gao C, Liu J, Falconi G, Valentini L, Gurnari C, Finelli C, Cocco L, Liu JH, Jones AI, Yang JY, Yang H, Thoms JAI, Unnikrishnan A, Pimanda JE, Pan R, Bassal MA, MT Voso*, Tenen DG*, Chai L*. Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy. *N*

ENG J MED 2022;386;21:1998-2010. (IF:176.079)

5. ^{2,5}Liu YC, Su CW, Ko PS, Lee RC, Liu CJ, Huang YH, Gau JP, Liu JH*. A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma. *Asia Pac J Clin Oncol* 2022;18:19-27. (IF:1.926)
6. ^{2,5}Tilly H*, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. *N Engl J Med* 2022;386:351-63. (IF:176.079)
7. ^{2,5}Tsai CY, Fang TP, Chen SW, Chen HW, Lin ECY, Lin TA, Tarng DC, Chang YI*. Di(2-ethylhexyl)phthalate impairs erythropoiesis via inducing Klotho expression and not via bioenergetic reprogramming. *Am J Transl Res* 2022;14:1234-5. (IF:3.940)
8. ^{2,5}Tsai XC, Chen TT, Gau JP, Wang PN, Liu YC, Lien MY, Li CC, Yao M, Ko BS*. Outcomes of Different Haploidentical Transplantation Strategies from the Taiwan Blood and Marrow Transplantation Registry. *Cancers (Basel)* 2022;14:1097. (IF:6.575)
9. ^{2,5}Wang YH, Hsieh CY, Hsiao LT, Lin TL, Liu YC, Yao M, Tan TD, Ko BS*. Stem cell transplant for mantle cell lymphoma in Taiwan. 2022;12:5662. (IF:4.996)
10. ^{2,5}Wu CH, Gau JP, Teng CLJ, Shih YH, Su YC, Wang RC, Chen TC*. Clinical Features and Immunophenotypes of Double-Hit Diffuse Large B-Cell Lymphoma. *Diagnostics* 2022; 12:1106. (IF:3.992)
11. ^{2,5}Wu WC, Lin TY, Chen MH, Hung YP, Lin CA, Lee RC, Huang YH, Chao Y, Chen SC*. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. *Invest New Drugs* 2022;40:789-97. (IF:3.651)
12. ^{2,5}Yao CY, Agathangelidis A, Chuang SS, Tsou HH, Feng WL, Liu TC, Chen TY, Yu YB, Yeh SP, Yao M, Wang CC, Lin J, Hwang WL, Gau JP, Chou WC, Chao TY, Lin LI, Tien HF, Ghia P, Wu SJ*. Distinct Immunogenetic Profiles of Chronic Lymphocytic Leukemia in Asia: A Taiwan Cooperative Oncology Group Registry Study. *Hemasphere* 2022;6:e803. (IF:8.300)

Allergy, Immunology and Rheumatology

1. ^{2,5}Chang YS, Chen JH, Lin ZM, Hsu HC, Chen WS, Lin SH, Kuo P, Lin YC, Chang CC*. Effects of biologics on reducing the risks of total knee replacement and total hip replacement in rheumatoid arthritis. *RHEUMATOLOGY* 2022;61:1849-56. (IF:7.046)
2. ^{2,5}Chen CH*, Chen HA, Liao HT, Chou CT, Chen CH*. Association of blood pressure and hypertension with radiographic damage among the patients with ankylosing spondylitis. *Medicine (Baltimore)* 2022;101:30811. (IF:1.817)
3. ^{2,5}Chuang HC, Chen MH, Chen YM, Ciou YR, Hsueh CH, Tsai CY, Tan TH*. Induction of Interferon-gamma and Tissue Inflammation by Overexpression of Eosinophil Cationic Protein in T Cells and Exosomes. *Arthritis Rheumatol* 2022;74:92-104. (IF:15.483)
4. ²Lai CC, Liu FL, Tsai CY, Wang SL, Chang DM*. Di-(2-ethylhexyl) phthalate exposure links to inflammation and low bone mass in premenopausal and postmenopausal females: Evidence

- from ovariectomized mice and humans. *Int J Rheum Dis* 2022;25:926-36. (IF:2.558)
5. ²Lai CC, Sun YS, Chen WS, Liao HT, Chen MH, Tsai CY, Huang DF, Chou CT, Chang DM*. Risk factors for mortality in systemic lupus erythematosus patients: Analysis of adult and pediatric cohorts in Taiwan. *J Chin Med Assoc* 2022;85:1044-50. (IF:3.396)
 6. ²Lee JY, Tsai CY, Liao HT*. Livedo racemosa and thrombotic vasculitides of scalp in systemic lupus erythematosus. *Ann Rheum Dis* 2022;81:1474. (IF:27.973)
 7. ²Li YT, Liao HT*. Relapsing polychondritis. *Joint Bone Spine* 2022;89:105387. (IF:5.263)
 8. ²Liao HT*. Efficacy of tocilizumab for refractory relapsing polychondritis with tracheal stenosis and respiratory distress. *Rheumatology* 2022;61:1293-4. (IF:7.046)
 9. ²Liao HT, Tsai CY*, Lai CC, Hsieh SC, Sun YS, Li KJ, Shen CY, Wu CH, Lu CH, Kuo YM, Li TH, Chou CT, Yu CL. The Potential Role of Genetics, Environmental Factors, and Gut Dysbiosis in the Aberrant Non-Coding RNA Expression to Mediate Inflammation and Osteoclastogenic/Osteogenic Differentiation in Ankylosing Spondylitis. *Front Cell Dev Biol* 2022;9:748063. (IF:6.081)
 10. ²Liao HT*, Tung HY, Chou CT, Tsai HC, Yen YN, Tsai CY. Immunogenicity of the mRNA-1273 and ChAdOx1 nCoV-19 vaccines in Asian patients with autoimmune rheumatic diseases under biologic and/or conventional immunosuppressant treatments. *Scand J Rheumatol* 2022;51:500-5. (IF:3.057)
 11. ²Lin KL, Chao TC, Chen MH*. Intravenous Immunoglobulin to Suppress Progression in a Patient With Advanced Breast Cancer. *J Breast Canc* 2022;25:253-8. (IF:2.922)
 12. ^{2,5}Shen YC, Hsu HC, Lin TM, Chang YS, Hu LF, Chen LF, Lin SH, Kuo PI, Chen WS, Lin YC, Chen JH, Liang YC, Chang CC*. H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection. *J Clin Oncol* 2022;40:1206-19. (IF:50.717)
 13. ²Su CF*, Liao HT, Tsai CY. Tocilizumab and rituximab for anti-MDA-5 positive amyopathic dermatomyositis complicated with macrophage activation syndrome and progressive fibrosing interstitial lung disease. *Scand J Rheumatol* 2022;51:166-8. (IF:3.057)
 14. ²Tsai HC, Tung HY, Liu CW, Su CF, Sun YS, Chen WS, Chen MH, Lai CC, Liao HT*, Yang YY, Huang YH, Tsai CY*. Significance of high serum IgG4 in complete or non-full-fledged IgG4-related disease-a retrospective investigation of 845 patients and its clinical relevance. *Clin Rheumatol* 2022;41:115-22. (IF:3.650)
 15. ^{2,5}Tsai YC, Tsao YP, Huang CJ, Tai YH, Su YC, Chiang CE, Sung SH, Chen CH, Cheng HM*. Effectiveness of salt substitute on cardiovascular outcomes: A systematic review and meta-analysis. *J Clin Hypertens* 2022;24:1147-60. (IF:2.885)
 16. ²Tsao YP, Yeh WY, Hsu TF, Chow LH, Chen WC, Yang YY, Shulruf B, Chen CH, Cheng HM*. Implementing a flipped classroom model in an evidence-based medicine curriculum for pre-clinical medical students: evaluating learning effectiveness through prospective propensity score-matched cohorts. *BMC Med Educ* 2022;22:185. (IF:3.263)
 17. ^{2,5}Wang CC, Tseng KS, Tsao YP, Chen WS, Lai CC, Sun YS, Liao HT, Chen MH*, Tsai CY*. Real-world effectiveness and safety of golimumab in rheumatoid arthritis treatment: A two-center study in Taiwan. *J Chin Med Assoc* 2022;85:175-82. (IF:3.396)
 18. ^{2,5}Wang HJ, Su CP, Lai CC, Chen WR, Chen C, Ho LY, Chu WC, Lien CY*. Deep Learning-

Based Computer-Aided Diagnosis of Rheumatoid Arthritis with Hand X-ray Images Conforming to Modified Total Sharp/van der Heijde Score. *Biomedicines* 2022;10:1355. (IF:4.757)

19. ^{2,5}Wang WH, Lai CC, Huang YF, Li TH, Tsao YP, Chen WS, Chang YS*. Pneumocystis Jirovecii Pneumonia in Systemic Lupus Erythematosus: A Nationwide Cohort Study in Taiwan. *Arthritis Care Res* 2022;74:1444-50. (IF:5.178)
20. ^{2,4}Wu TH, Hsieh SC, Li TH, Lu CH, Liao HT, Shen CY, Li KJ, Wu CH, Kuo YM, Tsai CY*, Yu CL. Molecular Basis for Paradoxical Activities of Polymorphonuclear Neutrophils in Inflammation/Anti-Inflammation, Bactericide/Autoimmunity, Pro-Cancer/Anticancer, and Antiviral Infection/SARS-CoV-II-Induced Immunothrombotic Dysregulation. *Biomedicines* 2022;10:773. (IF:4.757)
21. ^{2,4}Wu TH, Liao HT, Li TH, Tsai HC, Lin NC, Chen CY, Tsai SF, Huang TH, Tsai CY*, Yu CL. High-Throughput Sequencing of Complementarity Determining Region 3 in the Heavy Chain of B-Cell Receptor in Renal Transplant Recipients: A Preliminary Report. *J Clin Med* 2022;11:2980. (IF:4.964)
22. ¹Yu SF[#], Chen MH[#], Chen JF, Wang YW, Chen YC, Hsu CY, Lai HM, Chiu WC, Ko CH, He HR, Cheng TT. Establishment of a preliminary FRAX (R)-based intervention threshold for rheumatoid arthritis-associated fragility fracture: a 3-year longitudinal, observational, cohort study. *Ther Adv Chronic Dis* 2022;13:20406223221078089. (IF:4.970)

Clinical Toxicology and Occupational Medicine

1. ^{2,5}Chen SY, Chu FY*, Yang CY, Tarng DC. Flumazenil partially reverses gamma-hydroxybutyrate (GHB)-induced coma: a case report. *Am J Drug Alcohol Abuse* 2022;48:629-30. (IF:3.912)
2. ⁵Chen WL, Nithiyanantham S, Mao YC, Muo CH, Chuu CP, Liu SP, Huang MW, Su KP*. Haloperidol and Other Antipsychotics Exposure before Endometrial Cancer Diagnosis: A Population-based Case-control Study. *Clin Psychopharmacol Neurosci* 2022;20:526-35. (IF:3.731)
3. ^{2,5}Chen YT, Kao ZK, Shih CJ, Ou SM, Yang CY*, Yang AH, Lee OKS, Tarng DC. Magnesium exposure increases hip fracture risks in patients with chronic kidney disease: a population-based nested case-control study. *Osteoporosis Int* 2022;33:1079-87. (IF:5.071)
4. ²Cheng WY, Yang CY*, Tarng DC. Matcha-like ascites. *Ther Apher Dial* 2022;26:854-5. (IF:2.195)
5. ^{2,5}Lin CC, Weng T, Ng CJ, Shih CP, Hsu J, Liao YC, Yang CC*, Fang CC. Emergency department visits due to new psychoactive substances and other illicit drugs in Taiwan: preliminary results of the Taiwan Emergency Department Drug Abuse Surveillance (TEDAS) project. *Clin Toxicol* 2022;60:708-15. (IF:3.738)
6. ^{2,5}Ou HC, Deng JF, Yang CC, Lin CS, Mao YC, Tsai SH, Ho CH*. A successful experience using labetalol and hemodialysis to treat near-fatal caffeine poisoning: A case report with toxicodynamics. *Am J Emerg Med* 2022;55:224.e1-224.e4. (IF:4.093)
7. ^{2,4}Tsai HC, Ou SM, Wu CC, Huang CC, Hsieh JT, Tseng PY, Lee CY, Yang CY*, Tarng DC. Pentraxin 3 Predicts Arteriovenous Fistula Functional Patency Loss and Mortality in Chronic Hemodialysis Patients. *Am J Nephrol* 2022;53:148-56. (IF:4.605)

8. ^{2,5}Weng ZL, Chu FY, Li CL, Chen ZJ. Choices of Specialties and Training Sites among Taiwanese Physicians Graduating from Polish Medical Schools. *Int J Environ Res Public Health* 2022;19:3727. (IF:4.614)
9. ²Wu BS, Chu FY, Yang CY*. Water reduces iron toxicity. *Toxicol Ind Health* 2022;38:773-5. (IF:1.851)
10. ²Wu BS, Wei CLH, Yang CY, Lin MH, Hsu CC, Hsu YJ, Lin SH*, Tarng DC*. Mortality rate of end-stage kidney disease patients in Taiwan. *J Formos Med Assoc* 2022;121:S12-9. (IF:3.871)
11. ^{2,5}Wu CK, Tarng DC, Yang CY, Leu JG, Lin CH*. Factors affecting arteriovenous access patency after percutaneous transluminal angioplasty in chronic haemodialysis patients under vascular access monitoring and surveillance: a single-centre observational study. *BMJ Open* 2022;12:e055763. (IF:3.006)
12. ²Yang CY*, Wu BS, Wang YF, Lee YHW, Tarng DC. Weight-Based Assessment of Access Flow Threshold to Predict Arteriovenous Fistula Functional Patency. *Kidney Int Rep* 2022;7:507-15. (IF:6.234)

Transfusion Medicine

1. ^{2,5}Chen JL, Chu PY, Huang CT, Huang TT, Wang WL, Lee YH, Chang YY, Dai MS, Shiau CW, Liu CY*. Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma. *Mol Med* 2022;28:93. (IF:6.382)
2. ^{2,5}Cheng HF, Tsai YF*, Huang CC, Lien PJ, Wang YL, Hsu CY, Chen YJ, Liu CY, Chao TC, Lin YS, Feng CJ, Chiu JH, Chau GY, Tseng LM*. Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital. *J Chin Med Assoc* 2022;85:88-94. (IF:3.396)
3. ⁵Handa H, Cheong JW, Onishi Y, Iida H, Kobayashi Y, Kim HJ, Chiou TJ, Izutsu K, Tsukurov O, Zhou XF, Faessel H, Yuan Y, Sedarati F, Faller DV, Kimura A, Wu SJ*. Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine. *J Hematol Oncol* 2022;15:56. (IF:23.168)
4. ^{2,5}Huang CC, Tsai YF, Liu CY, Lien PJ, Lin YS, Chao TC, Feng CJ, Chen YJ, Lai JI, Phan NN, Hsu CY, Chiu JH, Tseng LM*. Prevalence of tumor genomic alterations in homologous recombination repair genes among Taiwanese breast cancers. *Ann Surg Oncol* 2022;29:3578-90. (IF:4.339)
5. ^{2,5}Huang CC, Tsai YF, Liu CY, Lien PJ, Lin YS, Chao TC, Feng CJ, Chen YJ, Lai JI, Phan NN, Hsu CY, Chiu JH, Tseng LM*. ASO Visual Abstract: Prevalence of tumor genomic alterations in homologous recombination repair genes among Taiwanese Breast Cancers. *Ann Surg Oncol* 2022;29(Suppl 3):618-9. (IF:4.339)
6. ^{2,5}Huang CP, Tsai YF, Lin YS, Liu CY, Huang TT, Huang CC, Chiu JH*, Tseng LM. Overexpression of multiple epidermal growth factor like domains 11 rescues anoikis survival through tumor cells-platelet interaction in triple negative breast cancer cells. *Life Sci* 2022;299:125041. (IF:6.780)
7. ^{2,5}Lai JI, Chao TC, Liu CY, Huang CC, Tseng LM*. A systemic review of taxanes and their

- side effects in metastatic breast cancer. *Front Oncol* 2022;12:940239. (IF:5.738)
8. ^{2,5}Lin CY, Yu CJ, Liu CY, Chao TC, Huang CC, Tseng LM, Lai JI*. CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin-proteasome pathway in ER plus breast cancer. *Clin Transl Oncol* 2022;24:2120-35. (IF:3.340)
 9. ^{2,5}Lin CY, Yu CJ, Liu CY, Chao TC, Huang CC, Tseng LM, Lai JI*. Correction to: CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin-proteasome pathway in ER + breast cancer (Aug, 10.1007/s12094-022-02881-0, 2022). *Clin Transl Oncol* 2022;24:2251-3. (IF:3.340)
 10. ^{2,5}Lin CY, Yu CJ, Shen CI, Liu CY, Chao TC, Huang CC, Tseng LM, Lai JI*. IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target. *Med Oncol* 2022;39:242. (IF:3.738)
 11. ^{2,5}Sun RL, Pan SW*, Feng JY, Liu CY, Chen YM. Osteoblastic flare phenomenon in a patient treated for disseminated non-tuberculous mycobacterial infection. *Thorax* 2022;77:1152-3. (IF:9.203)
 12. ³Wang X, Urak R, Walter M, Guan M, Han T, Vyas V, Chien SH, Gittins B, Clark MC, Mokhtari S, Cardoso A, Diamond DJ, Zaia J, Forman SJ, Nakamura R. Large-scale manufacturing and characterization of CMV-CD19CAR T cells. *J Immunother Cancer* 2022;10:e003461. (IF:12.469)

General Medicine

1. ^{2,5}Chen HY, Huang WC, Teng HI, Tsai CT, Tsai YL, Chuang MJ, Chen YY, Lu TM*. Effects of aggressive predilatation, sizing, and postdilatation strategy for coronary bioresorbable vascular scaffolds implantation. *J Chin Med Assoc* 2022;85:543-8. (IF: 3.396)
2. ^{2,5}Chiang CH, Chang CC, Huang HC, Chen YJ, Tsai PH, Jeng SY, Hung SI, Hsieh JH, Huang HS, Chiou SH*, Lee FY, Lee SD. Corrigendum to "Investigation of hepatoprotective activity of induced pluripotent stem cells in the mouse model of liver injury". *Biomed Res Int* 2022;2022:9794832. (IF:3.246)
3. ^{2,5}Chuang MJ, Chang CC, Lee YH, Lu YW, Tsai YL, Chou RH, Wu CH, Lu TM, Huang PH*. Clinical assessment of resting full-cycle ratio and fractional flow reserve for coronary artery disease in a real-world cohort. *Front Cardiovasc Med* 2022;9:988820. (IF:5.848)
4. ^{2,4}Hsu SJ, Huang HC, Pun CK, Chang CC*, Chuang CL, Huang YH, Hou MC, Lee FY. Sodium-glucose cotransporter-2 inhibition exacerbates hepatic encephalopathy in biliary cirrhotic rats. *J Pharmacol Exp Ther* 2022;383:25-31. (IF:4.404)
5. ²Huang HC, Chang CC, Pun CK, Tsai MH, Chuang CL, Hsu SJ*, Huang YH, Hou MC, Lee FY. α -Adrenergic blockade prevented environmental temperature reduction-induced transient portal pressure surge in cirrhotic and portal hypertensive rats. *Clin Sci (Lond)* 2022;136:1449-66. (IF:6.876)
6. ²Huang HC, Hsu SJ, Chang CC, Chuang CL, Hou MC, Lee FY. Effects of PCSK-9 inhibition by alirocumab treatments on biliary cirrhotic rats. *Int J Mol Sci* 2022;23:7378. (IF:6.208)
7. ²Huang HC, Hsu SJ, Chang CC*, Kao YC, Chuang CL, Hou MC, Lee FY. Lycopene treatment improves intrahepatic fibrosis and attenuates pathological angiogenesis in biliary cirrhotic rats. *J Chin Med Assoc* 2022;85:414-20. (IF:3.396)

8. ²Huang LJ, Chen SJ, Hu YW, Liu CY, Wu PF, Sun SM, Lee SY, Chen YY, Lee CY, Chan YJ, Chou YC, Wang FD*. The impact of antimicrobial stewardship program designed to shorten antibiotics use on the incidence of resistant bacterial infections and mortality. *Sci Rep* 2022;12:913. (IF:4.996)
9. ^{2,5}Huang PH, Lu YW, Tsai YL, Wu YW, Li HY, Chang HY, Wu CH, Yang CY, Tarng DC, Huang CC, Ho LT, Lin CF, Chien SC, Wu YJ, Yeh HI, Pan WH, Li YH*; expert committee for the Taiwan Lipid Guidelines for Primary Prevention. 2022 Taiwan lipid guidelines for primary prevention. *J Formos Med Assoc* 2022;121:2393-407. (IF:3.871)
10. ^{2,4}Huang SF*, Huang YC, Lee CT, Chou KT, Chen HP, Huang CC, Ji DD, Chan YJ, Yang YY. Cytomegalovirus viral interleukin-10 in patients with Aspergillus infection and effects on clinical outcome. *Mycoses* 2022;65:760-9. (IF:4.931)
11. ^{2,4}Lee PC, Chang TE, Wang YP, Lee KC, Lin YT, Chiou JJ, Huang CW, Yang UC, Li FY, Huang HC, Wu CY, Huang YH, Hou MC*. Alteration of gut microbial composition associated with the therapeutic efficacy of fecal microbiota transplantation in *Clostridium difficile* infection. *J Formos Med Assoc* 2022;121:1636-46. (IF:3.871)
12. ^{1,5}Lin YK, Tsai KZ, Han CL, Lee JT, Lin GM*. Athlete's Heart Assessed by Sit-Up Strength Exercises in Military Men and Women: The CHIEF Heart Study. *Front Cardiovasc Med* 2022;8:737607. (IF:5.846)
13. ^{2,5}Lu DY, Huang WM, Wang WT, Hung SC, Sung SH, Chen CH, Yang YJ, Niu DM, Yu WC*. Reduced global longitudinal strain as a marker for early detection of Fabry cardiomyopathy. *Eur Heart J-Cardiovasc Imaging* 2022;23:487-95. (IF:9.130)
14. ^{2,5}Lu YW, Chang CC, Chou RH, Tsai YL, Liu LK, Chen LK, Huang PH*, Lin SJ. Sex difference in the association between pathological albuminuria and subclinical atherosclerosis: insights from the I-Lan longitudinal aging study. *Aging (Albany NY)* 2022;14:8001-12. (IF: 5.955)
15. ^{2,5}Sy CL, Chen PY, Cheng CW, Huang LJ, Wang CH, Chang TH, Chang YC, Chang CJ, Hii IM, Hsu YL, Hu YL, Hung PL, Kuo CY, Lin PC, Liu PY, Lo CL, Lo SH, Ting PJ, Tseng CF, Wang HW, Yang CH, Lee SSJ*, Chen YS, Liu YC, Wang FD. Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms. *J Microbiol Immunol Infect* 2022;55:359-86. (IF:10.273)
16. ^{2,5}Tsai CT, Huang WC, Lu YW, Teng HI, Huang SS, Tsai YL, Lee WL, Lu TM*. Obesity paradox in patients with chronic total occlusion of coronary artery. *Eur J Clin Invest* 2022;52:e13698. (IF: 5.722)
17. ²Tsai YL, Chou RH, Lu YW, Chang CC, Kuo CS, Huang PH*, Chen JW, Lin SJ. Associations between galectin-1, left ventricular diastolic dysfunction, and heart failure with preserved ejection fraction. *J Cardiol* 2022;79:371-5. (IF:2.974)
18. ^{2,5}Sheng WH, Ho YL, Jenq CC, Chuang CL, Chen CY, Tsai MJ, Yang YS, Wu MS, Chang SC*. Longitudinal assessment of milestone development among internal medicine residents in Taiwan. *J Formos Med Assoc* 2022;121:2281-7. (IF:3.871)

Endoscopy Center For Diagnosis and Treatment

1. ²Chang TE, Su CW, Huang YS, Huang YH, Hou MC, Wu JC*. Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono

- infection: A meta-analysis. *J Chin Med Assoc* 2022;85:30-41. (IF:3.396)
2. ^{2,5}Chen PH, Lai HK, Yeh YC, Chang KW, Hou MC, Kuo WC*. En-face polarization-sensitive optical coherence tomography to characterize early-stage esophageal cancer and determine tumor margin. *Biomed Opt Express* 2022;13:4773-86. (IF:3.562)
 3. ^{2,4}Hsieh YC, Wu PS, Lin YT, Huang YH, Hou MC, Lee KC*, Lin HC. (Pro)renin receptor inhibition attenuated liver steatosis, inflammation, and fibrosis in mice with steatohepatitis. *Faseb J* 2022;36:e22526. (IF:5.834)
 4. ^{2,5}Jheng YC, Wang YP, Lin HE, Sung KY, Chu YC, Wang HS, Jiang JK, Hou MC, Lee FY, Lu CL*. A novel machine learning-based algorithm to identify and classify lesions and anatomical landmarks in colonoscopy images. *Surg Endosc* 2022;36:640-50. (IF:3.453)
 5. ^{2,4}Lee PC, Chang TE, Wang YP, Lee KC, Lin YT, Chiou JJ, Huang CW, Yang UC, Li FY, Huang HC, Wu CY, Huang YH, Hou MC*. Alteration of gut microbial composition associated with the therapeutic efficacy of fecal microbiota transplantation in *Clostridium difficile* infection. *J Formos Med Assoc* 2022;121:1636-46. (IF:3.871)
 6. ^{2,5}Lu HS, Yang TC, Chang CY, Huang YH, Hou MC*. The risk of variceal bleeding during endoscopic retrograde cholangiopancreatography. *J Chin Med Assoc* 2022;85:896-900. (IF:3.396)
 7. ^{2,4}Pan YL, Wu PS*, Chen JH, Chen LY, Fang WL, Chau GY, Lee KC, Hou MC. Early cholecystectomy following percutaneous transhepatic gallbladder drainage is effective for moderate to severe acute cholecystitis in the octogenarians. *Arch Gerontol Geriatr* 2022;106:104881. (IF:4.163)
 8. ^{2,4}Pan YL, Wu PS*, Ye BW, Li CP, Lee IC, Lee KC*, Huang YH, Hou MC. Outcomes of patients with malignant esophagogastric junction obstruction receiving metallic stents: A single-center experience. *J Chin Med Assoc* 2022;85:160-6. (IF:3.396)
 9. ²Sung KI, Wang YP*, Chang TE, Wang HS, Jiang JK, Luo JC, Lee FY, Hou MC, Lu CL. Safety and importance of colonoscopy in nonagenarians. *J Chin Med Assoc* 2022;85:304-10. (IF:3.396)
 10. ²Sung KY, Chang TE, Wang YP*, Lin CC, Chang CY, Hou MC, Lu CL. SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis. *J Chin Med Assoc* 2022;85:421-30. (IF:3.396)
 11. ²Sung KY, Zhang B, Wang HHE, Bai YM, Tsai SJ, Su TP, Chen TJ, Hou MC, Lu CL, Wang YP*, Chen MH*. Schizophrenia and risk of new-onset inflammatory bowel disease: a nationwide longitudinal study. *Aliment Pharmacol Ther* 2022;55:1192-201. (IF:9.524)
 12. ^{2,5}Tsai CF, Chuang CH, Wang YP, Lin YB, Tu PC, Liu PY, Wu PS, Lin CY, Lu CL*. Differences in gut microbiota correlate with symptoms and regional brain volumes in patients with late-life depression. *Front Aging Neurosci* 2022;14:885393. (IF:5.702)
 13. ²Wang YP, Jheng YC, Sung KY, Lin HE, Hsin IF, Chen PH, Chu YC, Lu D, Wang YJ, Hou MC, Lee FY, Lu CL*. Use of U-Net Convolutional Neural Networks for Automated Segmentation of Fecal Material for Objective Evaluation of Bowel Preparation Quality in Colonoscopy. *Diagnostics* 2022;12:613. (IF:3.992)
 14. ^{2,5}Wei TH, Ye BW, Wu PS*, Li CP, Chao Y, Lee PC, Huang YH, Lee KC*, Hou MC. Outcomes of patients with malignant duodenal obstruction after receiving self-expandable metallic stents: A single center experience. *PLoS One* 2022;17:e0268920. (IF:3.752)

15. ^{2,5}Xiao YL, Wu JCY, Lu CL, Tseng PH, Lin L, Hou XH, Li YQ, Zou DW, Lv B, Xiang XL, Dai N, Fang XC, Chen MH*. Clinical practice guidelines for esophageal ambulatory reflux monitoring in Chinese adults. *J Gastroenterol Hepatol* 2022;37:812-22. (IF:4.369)
16. ^{2,4}Yang TC, Chen PH, Hou MC*, Peng LN, Lin MH, Chen LK, Huang YH. Antiperistaltic effect and safety of l-menthol for esophagogastroduodenoscopy in the elderly with contraindication to hyoscine-N-butylbromide. *Sci Rep* 2022;12:10418. (IF:4.996)
17. ^{2,4}Ye YC, Wang SE, Wang YP*. Ileoileal intussusception caused by ileal neuroendocrine carcinoma. *Clin Gastroenterol Hepatol* 2022;20:A29-30. (IF:13.576)
18. ^{2,5}Zhan B, Wang HH, Bai YM, Tsai SJ, Su TP, Chen TJ, Wang YP*, Chen MH*. Bidirectional association between inflammatory bowel disease and depression among patients and their unaffected siblings. *J Gastroenterol Hepatol* 2022;37:1307-15 (IF: 4.369)

Hospitalist Medicine

1. ^{2,4}Chang TE, Su CW*, Huang YS, Huang YH, Hou MC, Wu JC*. Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: A meta-analysis. *J Chin Med Assoc* 2022;85:30-41. (IF:3.396)
2. ^{2,4}Chang YS, Su CW, Chen SC, Chen YY, Liang YJ, Wu JC*. Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance. *Cells* 2022;11:624. (IF:7.666)
3. ^{2,5}Chen WT, Lo LW*, Tsai WC, Lin YJ, Chang SL, Hu YF, Chung FP, Liao JN, Tuan TC, Chao TF, Lin CY, Chang TY, Kuo L, Liu CM, Liu SH, Cheng WH, Lin LD, Ton ANK, Hsu CY, Chheng C, Elimam A, Wang HS, Kuo MR, Kao PH, Chen SA*. Application of dynamic display technology to identify gaps after pulmonary vein isolation in catheter ablation of atrial fibrillation. *J Cardiol* 2022;80:34-40. (IF:2.974)
4. ^{2,4}Chen YJ, Su CW, Wei CY, Chau GY, Chen PH, Chao Y, Huang YH, Wu JC, Yang TC, Lee PC, Hou MC*. Comparison of prognoses between cirrhotic and noncirrhotic patients with hepatocellular carcinoma and esophageal varices undergoing surgical resection. *J Chin Med Assoc* 2022;85:679-86. (IF:3.396)
5. ^{2,5}Chen YY, Kuo MJ, Chung FP, Lin YJ*, Chien KL, Hsieh YC, Chang SL, Lo LW, Hu YF, Chao TF, Liao JN, Chang TY, Lin CY, Kuo L, Tuan TC, Wu CI, Liu CM, Liu SH, Li CH, Chen SA. Risks of Ventricular Tachyarrhythmia and Mortality in Patients with Amyloidosis - A Long-Term Cohort Study. *Acta Cardiol Sin* 2022;38:464-74. (IF:1.80)
6. ^{2,5}Cheng WH, Lo LW*, Lin YJ, Chang SL, Hu YF, Chung FP, Tuan TC, Chao TF, Liao JN, Chang TY, Lin CY, Kuo L, Liu SH, Vicera JJ, Lugtu IC, Kim S, Chen SA*. Identification of Circumferential Pulmonary Vein Isolation Gaps and Critical Atrial Substrate From HD Grid Maps in Atrial Fibrillation Patients: Insights From Omnipolar Technology. *Circ-Arrhythmia Electrophysiol* 2022;15:63-5. (IF:7.718)
7. ^{2,5}Chhay C, Hsu CY, Chang SL*, Lin YJ, Lo LW, Hu YF, Chung FP, Chang TY, Lin CY, Hung Y, Liu CM, Kuo L, Liu SH, Ahli L, Kuo MJ, Cheng WH, Kao PH, Chen WT, Khac TCN, Lin WS, Chen SA. Electrophysiological characteristics of epicardial breakthrough during catheter ablation of perimitral atrial flutter. *Front Cardiovasc Med* 2022;9:1030916. (IF:5.848)
8. ^{2,5}Ho SE, Liu PH, Hsu CY, Huang YH, Liao J, Su CW, Hou MC, Huo TA*. Tumor burden

- score as a new prognostic surrogate in patients with hepatocellular carcinoma undergoing radiofrequency ablation: role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. *Expert Rev Gastroenterol Hepatol* 2022;16:903-11. (IF:4.095)
9. ^{2,5}Ho SY, Liu PH, Hsu CY, Huang YH, Liao JI, Su CW, Hou MC, Huo TI*. A New Tumor Burden Score and Albumin-Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma. *Cancers* 2022;14:649. (IF:6.575)
 10. ^{2,5}Ho SY, Liu PH, Hsu CY, Huang YH, Liao JI, Su CW, Hou MC, Huo TI*. Radiofrequency Ablation versus Transarterial Chemoembolization for Hepatocellular Carcinoma within Milan Criteria: Prognostic Role of Tumor Burden Score. *Cancers* 2022;14:4207. (IF:6.575)
 11. ^{2,4}Huang KW, Lee PC, Chao Y, Su CW, Lee IC, Lan KH, Chu CJ, Hung YP, Chen SC, Hou MC, Huang YH*. Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma. *Ther Adv Med Oncol* 2022;14:17588359221099401. (IF:5.485)
 12. ^{2,5}Kao PH, Chung FP*, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chao TF, Liao JN, Lin CY, Chang TY, Kuo L, Wu CI, Liu CM, Liu SH, Cheng WH, Lin L, Ton AKN, Hsu CY, Chhay C, Chen SA. Application of Ensite (TM) LiveView function for identification of scar-related ventricular tachycardia isthmus. *J Cardiovasc Electrophysiol* 2022;33:1223-33. (IF:2.942)
 13. ^{2,5}Kao WY, Su CW*. Outcomes of atezolizumab and bevacizumab for hepatocellular carcinoma: Does age matter?. *Liver Int* 2022;42:2597-8. (IF:8.754)
 14. ^{2,4}Ko CC, Ho SY, Liu PH, Hsu CY, Hsia CY, Huang YH, Su CW, Lei HJ, Lee RC, Hou MC, Huo TI*. Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin-bilirubin grade. *Int J Clin Oncol* 2022;27:739-48. (IF:3.850)
 15. ^{2,4}Kuo MJ, Lo LW*, Lin YJ, Chang SL, Hu YF, Chung FP, Tuan TC, Chao TF, Liao JN, Chang TY, Lin CY, Kuo L, Wu CI, Liu CM, Cheng WH, Liu SH, Ton AKN, Chhay C, Kao PH, Chen WT, Hsu CY, Kim S, Chen SA*. Low voltage zones detected by omnipolar Vmax map accurately identifies the potential atrial substrate and predicts the AF ablation outcome after PV isolation. *Int J Cardiol* 2022;351:42-7. (IF:4.039)
 16. ^{2,4}Lee CY, Chau GY, Wei CY, Chao Y, Huang YH, Huo TI, Hou MC, Su YH, Wu JC, Su CW*. Surgical resection could provide better outcomes for patients with hepatocellular carcinoma and tumor rupture. *Sci Rep* 2022; 12:8343. (IF:4.996)
 17. ^{2,4}Lee IC*, Lan KH, Su CW, Li CP, Chao Y, Lin HC, Hou MC, Huang YH*. Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy. *Int J Mol Sci* 2022; 23:11335. (IF:6.208)
 18. ^{2,4}Lee IC*, Lee PC, Chao Y, Chi CT, Wu CJ, Hung YP, Su CW, Hou MC, Huang YH*. Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment. *Viruses-Basel* 2022;14:2355. (IF:5.818)
 19. ^{2,5}Li CH, Lo LW*, Jain A, Hsieh YC, Lin YJ, Chang SL, Chung FP, Hu YF, Chao TF, Liao JN, Chang TY, Lin CY, Lugtu IC, Ton ANK, Liu SH, Cheng WH, Liu CM, Wu CI, Chen SA*. Patterns and Characteristics of SKYLINE-Lumipoint Feature in the Catheter Ablation of Atypical Atrial Flutter: Insight from a Novel Lumipoint Module of Rhythmia Mapping

- System. *J Pers Med* 2022;12:1102. (IF:3.508)
20. ^{2,5}Li GY, Chung FP*, Chao TF, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chang TY, Kuo L, Wu CI, Liu CM, Liu SH, Cheng WH, Chen SA. Sinus Node Dysfunction after Successful Atrial Flutter Ablation during Follow-Up: Clinical Characteristics and Predictors. *J Clin Med* 2022;11:3212. (IF:4.964)
 21. ^{2,4}Liao CY, Lee CY, Wei CY, Chao Y, Huang YH, Hou MC, Su YH, Wu JC, Su CW*. Differential prognoses among male and female patients with hepatocellular carcinoma. *J Chin Med Assoc* 2022;85:554-65. (IF:3.396)
 22. ^{2,5}Lin WL, Lai CT, Yamada S, Liu SH, Cheng WH, Chou YH, Yang CCH, Kuo TBJ*, Chen SA, Lo LW*. Effects of renal denervation on sleep apnea and arrhythmia in rats with myocardial infarction. *Sleep Med* 2022;91:115-23. (IF:4.842)
 23. ^{2,4}Liu YC[#], Su CW[#], Ko PS, Lee RC, Liu CJ, Huang YH, Gau JP, Liu JH*. A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma. *Asia-Pac J Clin Oncol* 2022;18:19-27. (IF:1.926)
 24. ^{2,5}Lugtu IC, Cheng WH, Chang SL, Liu SH, Lo LW*, Chen SA. Percutaneous Left Atrial Appendage Closure Using an Occluder Device: A Single Center Experience. *Acta Cardiol Sin* 2022;38:352-61. (IF:1.800)
 25. ^{2,4}Su PS, Wu SH, Chu CJ*, Su CW, Lin CC, Lee SD, Wang YJ, Lee FY, Huang YH, Hou MC. Sofosbuvir-based antiviral therapy provided highly treatment efficacy, safety, and good tolerability for Taiwanese chronic hepatitis C patients with decompensated cirrhosis. *J Chin Med Assoc* 2022;85:152-9. (IF:3.396)
 26. ^{2,5}Sung WT, Lo LW*, Lin YJ, Chang SL, Hu YF, Chung FP, Liao JN, Tuan TC, Chao TF, Lin CY, Chang TY, Kuo L, Liu CM, Liu SH, Cheng WH, Ton AKN, Hsu CY, Chhay C, Elimam AM, Kuo MJ, Kao PH, Chen WT, Chen SA. Alteration of Skin Sympathetic Nerve Activity after Pulmonary Vein Isolation in Patients with Paroxysmal Atrial Fibrillation. *J Pers Med* 2022;12:1286. (IF:3.508)
 27. ²Ton ANK[#], Liu SH[#], Lo LW*, Khac TCN, Chou YH, Cheng WH, Lin WL, Peng TY, Lin PY, Chang SL, Chen SA. Renal artery denervation prevents ventricular arrhythmias in long QT rabbit models. *Sci Rep* 2022;12:2904. (IF: 4.996)
 28. ²Tsai YC[#], **Tsao YP[#]**, Huang CJ, Tai YH, Su YC, Chiang CE, Sung SH, Chen CH, Cheng HM. Effectiveness of salt substitute on cardiovascular outcomes: A systematic review and meta-analysis. *J Clin Hypertens (Greenwich)* 2022;24:1147-60. (IF: 2.885)
 29. ²**Tsao YP**, Yeh WY, Hsu TF, Chow LH, Chen WC, Yang YY, Shulruf B, Chen CH, Cheng HM*. Implementing a flipped classroom model in an evidence-based medicine curriculum for pre-clinical medical students: evaluating learning effectiveness through prospective propensity score-matched cohorts. *BMC Med Educ* 2022;22:185. (IF: 3.232)
 30. ^{2,5}Wang CC, Tseng KS, Tsao YP, Chen WS, Lai CC, Sun YS, Liao HT, Chen MH*, Tsai CY*. Real-world effectiveness and safety of golimumab in rheumatoid arthritis treatment: A two-center study in Taiwan. *J Chin Med Assoc* 2022;85:175-82. (IF:3.396)
 31. ²Yu HY, Lee CY, Lin LG, Chao Y, Li CP*. Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience. *J Chin Med Assoc* 2022;85:42-50. (IF:3.396)

32. ²Yu HY, Li CP, Huang YH, Hsu SJ, Wang YP, Hsieh YC, Fang WL, Huang KH, Li AFY, Lee RC, Lee KL, Wu YH, Lai IC, Yang WC, Hung YP, Wang YC, Chen SH, Chen MH*, Chao Y*. Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer. *Cancers* 2022;14:218. (IF:6.575)
33. ^{2,5}Yugo D, Chen YY, Lin YJ*, Chien KL, Chang SL, Lo LW, Hu YF, Chao TF, Chung FP, Liao JN, Chang TY, Lin CY, Tuan TC, Kuo L, Wu CI, Liu CM, Liu SH, Li CH, Hsieh YC*, Chen SA. Long-term mortality and cardiovascular outcomes in patients with atrial flutter after catheter ablation. *Europace* 2022;24:970-8. (IF:5.486)
34. ^{2,5}Yugo D, Kuo MJ, Hu YF*, Liu CM, Lin YJ, Chang SL, Lo LW, Chao TF, Chung FP, Liao JN, Chang TY, Lin CY, Tuan TC, Kuo L, Liu SH, Ton ANK, Chhay C, Elimam A, Chen SA. Dynamic changes in signal-averaged P wave after catheter ablation of atrial fibrillation. *J Chin Med Assoc* 2022;85:549-53. (IF:3.396)